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Aims: The goal of this project was to evaluate the effectiveness of stem cells in 
heart failure to optimize them for clinical use. 
Methods: In the meta-analysis, randomized controlled clinical trials (RCTs) of stem 
cell treatments for heart failure were retrieved. Primary outcomes were set as all-cause 
mortality and left ventricular ejection fraction (LVEF) change from baseline. Mean 
differences and standard deviations between cell therapies and controls were calculated 
and separated into subgroups based on methodological and clinical differences. In the 
laboratory, stem cells were expanded with different medium sera and further brought to 
a severe condition that simulated ischemia-reperfusion injury (AcS). Cell counts and 
necrotic, apoptotic cells were assessed, and reverse transcription-polymerase chain 
reaction (RT-PCRs) were performed to measure cell proliferation, cell survival, and 
gene regulations under normal and stressful conditions. 
Results: 42 RCTs were retrieved, and 1984 participants were enrolled. Overall, 
stem cells were proven to reduce mortality and increase ∆LVEF by 2.88% and 2.33% at 
short- and long-term follow-ups. Results from trial quality assessments and sensitivity 
analyses indicated existence of bias risks in randomization and performance that 
significantly affect clinical outcomes lead to false-positive results. Among various cell 
origins, perinatal stem cells showed 6.48% and 5.22% of LVEF increase. Cord blood-
derived mesenchymal stromal cells were chosen for in vitro study. Under human sera, 
they presented a higher proliferative capacity and shorter expansion time. A higher 
survival rate was also confirmed against oxidative stress, but apoptosis- and cell cycle-
related genes were not regulated in a similar pattern under different medium sera. 
Conclusions: Overall, stem cell therapy did not show clinical values for improving 
cardiac contractility in patients with impaired heart functions. The outcomes were 
significantly influenced by poor blinding methods leading to false-positive results. 
Optimizing cord blood-derived mesenchymal stem cells (CB-MSCs) through human 
sera applications seems to be promising due to better performance in proliferation and 




Ziele: Dieser Arbeit liegt das Ziel zu Grunde die Wirksamkeit von Stammzellen bei 
Herzinsuffizienz zu evaluieren, um sie für den klinischen Einsatz zu optimieren. 
Methoden: In einer Metaanalyse wurden randomisierte kontrollierte klinische Studien 
zu Stammzellbehandlungen für HFrEF abgerufen. Die primären Ergebnisse wurden als 
Gesamtmortalität und LVEF-Änderung gegenüber dem Ausgangswert festgelegt. Die 
mittleren Unterschiede und ihre Standardabweichungen zwischen Zelltherapien und 
Kontrollen wurden berechnet und auf der Grundlage methodischer und klinischer 
Unterschiede in Untergruppen unterteilt. Im Labor wurden Stammzellen mit dem Zusatz 
von humanem Serum von Herzinsuffizienzpatienten vermehrt. Diese Stammzellen 
wurden dann einer modellierten Ischämie-Reperfusionsverletzung (AcS) ausgesetzt. 
Zellzahlen und nekrotische sowie apoptotische Zellen wurden quantifiziert und RT-PCRs 
wurden durchgeführt, um die Zellproliferation, das Zellüberleben und die Genregulation 
unter regulären und AsC-Bedingungen zu messen. 
Ergebnisse: 42 RCTs wurden abgerufen und 1984 Patienten wurden eingeschlossen. 
Insgesamt konnte gezeigt werden, dass Stammzellen die Mortalität senken und den 
∆LVEF bei kurz- und langfristigen Nachuntersuchungen um 2,88% bzw. 2,33% erhöhen. 
Studienqualitätsbewertungen und Sensitivitätsanalysen ergaben, dass 
Verzerrungsrisiken bei der Randomisierung und Leistung einen signifikanten Einfluss auf 
die klinischen Ergebnisse haben können, die zu falsch positiven Ergebnissen führen. Von 
allen untersuchten Zelltyoen zeigten perinatale Stammzellen einen Anstieg von 6,48% 
und 5,22% der LVEF. Aus Nabelschnurblut stammende mesenchymale Stromazellen 
wurden für eine in-vitro-Studie ausgewählt. Unter humanen Seren von 
Herzinsuffizienzpatienten zeigten sie eine höhere Proliferationskapazität und eine 
kürzere Expansionszeit. Eine höhere Überlebensrate wurde auch unter oxidativen Stress 
bestätigt, aber Apoptose- und Zellzyklus-bezogene Gene wurden unter verschiedenen 
mittleren Seren nicht in einem ähnlichen Muster reguliert. 
Schlussfolgerungen: Insgesamt zeigte die Stammzelltherapie zur Verbesserung der 
Herzkontraktibilität bei Patienten mit Herzfunktionsstörungen bislang keine klinischen 
Werte. Darüber hinaus wurden die Ergebnisse signifikant durch schlechte Blindheit 
beeinflusst, die zu falsch positiven Ergebnissen führte. Die Optimierung von CB-MSCs 
durch die Anwendung von Humanseren scheint vielversprechend zu sein, da die 
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Part I Meta-analyses of stem cell therapies for heart failure patients 




Heart failure with reduced ejection fraction (HFrEF) refers to cardiac pump failure 
that presents a series of symptoms such as shortness of breath, insufficient exercise 
capacity, swelling in the lower legs and feet, fatigue and weakness, etc., which is mostly 
caused by coronary artery disease. Approximately 40 million people in the world are 
impaired by heart failure1, a condition associated with a 5-year mortality rate of nearly 
50%2 which causes a tremendous burden to health care and leads to loss of many human 
lives. In contrast to other organs like the liver and epithelium that have significant 
capability for structure repair, the human heart is known to have very limited regenerative 
capacity. This is mainly due to the fact that its own pools of cardiac progenitor cells are 
rapidly depleted after myocardial infarction3. However, mobilized peripheral stem cells 
are insufficient to compensate adequately for the gap between rapid loss of 
cardiomyocytes after infarction and successive loss during the post-infarct inflammatory 
response. This lead to the idea of stem cell transplantation with the goal to fill that specific 
gap. 
After infarction, three phases of inflammatory responses are considered to be critical 
to myocardial repair: clearance of dead cells in the inflammatory phase, secretion of 
extracellular matrix proteins by myofibroblasts in the proliferative phase, and apoptosis of 
the majority of reparative cells and scar formation in the maturation phase4. The 
inflammatory response dominats gene expressions in the heart tissues after MI such that 
pro-inflammatory genes (such as IL-6, MCP-1, G-CSF, GM-CSF) were up-regulated while 
gene expressions of stem cell attractants (SDF-1, SCF) or angiogenesis (VEGF-a, VEGF-
R2) showed a slight decrease5. Although the inflammatory response is part of the healing 
process, prolonged and overshooting inflammation induces sustained loss of 
cardiomyocytes and matrix degradation, which causes ventricular chamber dilation and 
finally leads to heart failure. In contrast to myocardial infarction (MI), the main features 
during the progression of heart failure are fibrosis and ventricular remodeling. The 
etiologies of heart failure are not restricted to ischemic heart disease, but also rheumatism 
and idiopathic cardiomyopathy. Thus, the purpose of stem cell therapies for heart failure 
is to both reverse ventricular dilation and to improve systolic function. 
In early 1995, the achievement of producing high yield and pure skeletal myoblasts 
by Yoon6 elicited significant enthusiasm for stem cell-related heart failure treatment. In 
the author’s study, the harvested myoblasts were injected into dog hearts and later 
differentiated into cardiac muscle cell-like cells. In the following twenty years, extensive 
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preclinical and clinical experiments using stem cells for heart failure were completed and 
a variety of therapeutic approaches were exploited.  
An introduction to stem cell research for heart failure treatment based on data 
obtained mainly from preclinical trials is given below.  
Cell Type 
Myoblasts were the earliest stem cells to be investigated for HF treatment. At first, 
they were favored for their resistance to oxidative stress existing during heart failure and 
their myogenic capacity but were later proven to be more vulnerable compared to 
mesenchymal stem cells7,8. Even more, they were found to be pro-arrhythmia and 
tumorigenic9,10 (Details of advantages and disadvantages are listed in Table 1 and Figure 
1). Another type of cardiomyogenic skeletal muscle-derived stem cell that elicited the 
researchers’ interest were muscle-derived stem cells (MDSCs)7. Their differentiation 
potential is more similar to mesenchymal stem cells and has been proven to be 
osteogenic, chondrogenic, cardiomyogenic, and even hematopoietic11,12. Moreover, 
MDSCs are immune evasive due to their lack of major histocompatibility complex (MHC) 
expression13. They aree reported to be more efficient in cardiac regeneration compared 
to myoblasts, due to more active paracrine secretion9. The above-mentioned advantages 
are encouraging, however, induced arrhythmias are a prevalent problem that has to be 
solved urgently 14. 
Mesenchymal stromal cells (MSCs) are multipotent stem cells that can be isolated 
from a variety of tissues, including bone marrow, adipose tissue, heart, perinatal tissues, 
and other sources. MSCs have following characteristics associated with them in the 
context of myocardial repair: 
> Low immunogenicity 
> They are not known to be tumerogenic 
> Resistance to stressful microenvironments in ischemic region 
> They do not cause ventricular arrhythmias 
> They facilitate an immunomodulatory response vial paracrine signaling15,16.  
Adipose tissue-derived mesenchymal stem cells (ATMSCs) with easier accessibility and 
higher VEGF and HGF secretion are reported to be more efficient in HF treatment 
compared to bone marrow-derived mesenchymal stem cells (BMMSCs)17,18. Perinatal 
MSCs (such as umbilical cord-derived mesenchymal stromal cells [UCMSCs], cord blood-
derived mesenchymal stromal cells [CBMSCs] and others ) were shown to be even less 
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immunogenic19,20 and more advantageous in anti-inflammation and 
neovascularization21,22. The biggest advantages of UCMSCs over the other two origins of 
MSCs are their accessibility and the fact that there are no associated ethical issues. 
MSCs are believed to improve impaired cardiac functions through a paracrine mechanism 
instead of cardiomyogenesis. In contrast to skeletal muscle-derived stem cells, there is a 
lack of evidence that MSCs differentiate into cardiomyocyte-like cells in vivo. In vitro 
cardiomyocyte differentiation is proven to be feasible by 5-Azacytidine; nevertheless, it 
has no value for clinical application because of its toxicity23,24.  
 Bone marrow mononuclear cells (BMMNCs) are the unfractionated stem cells 
isolated from bone marrow aspirates that have been used primarily in clinical application. 
Another similar product is the adipose-derived stromal vascular fraction (AT-SVF). Both 
can be quickly infused into target areas after collection instead of long-term in vitro 
expansion. Furthermore, immunoselected purified-constituent subsets, for instance 
CD34+, were explored and demonstrated to lead to improved cardiac functions after 
transplantations compared to BMMNCs25. Likewise, STRO-3+ mesenchymal progenitor 
cells (MPCs), directly immunoselected from BMMNCs by STRO-3 antibody and 
expanded during cultivation, are considered to be subsets of BMMSCs with an even, 
purified constituent of regenerative cells. Another cell product from BMMNCs is 
Ixmyelocel-Ts. Through specific expansion techniques, MSCs and macrophages are 
expanded over 50 to 200-fold, while the amounts of other cell components shrink. 
Ixmyelocel-Ts have advantages over other cell types in anti-inflammation, so they are 
promising for suppressing immunological reactions after MI or during HF. 
Endogenous cardiac stem/progenitor cells (CSCs/CPCs) are believed to have large 
potential in heart regeneration. They are more effective than other cell types in improving 
cardiac function, without inducing ventricular arrhythmias and tumorigenesis26,27. 
Contrarily, they are found to decrease the incidence of arrhythmias28,29. However, they 
need long-term in-vitro expansion before cell infusion due to the tiny amount of isolated 
primary cells from the collection and immunosuppressive therapy is needed during 
allogeneic transplantation, which limits their widespread application. 
To date, pluripotent stem cells, such as embryonic stem cells (ESCs) and induced 
pluripotent stem cells (iPSCs), do not show any promise for widespread use in humans, 
owing to their tumorigenic effects30,31. In contrast, induced pluripotent stem cell-derived 
cardiomyocytes (iPSC-CMs) are considered to be a stem cell option despite the induction 
of arrhythmias and tumorigenesis32,33. Long-term laboratory preparation is still required 
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due to reprogramming and differentiation. Counterintuitively, immune rejection still 
happens during autologous transplantation because genetic modifications could cause 
immunogenicity of autologous iPSC-derived cells34. Potential causes include low MHC-I 
levels, genetic and epigenetic changes, xenogeneic or non-physiological culture reagents, 
gene corrections for the treatment of specific diseases, and other factors. Although iPSC-
CMs are proven to be quite similar to adult cardiomyocytes based on gene expression 
analysis35, this advantage could be turned into a disadvantage. iPSC-derived 
cardiomyocytes could also be vulnerable to the same unfavorable microenvironments 
that cause successive loss of the original cardiomyocytes. Also, insufficient engraftment 
of iPSC-CMs makes it very difficult to detect improvements in cardiac function. 
In summary, the advantages and disadvantages of stem cells for cardiac repair are 
listed in Table 1 and Figure 1. From existing results, we can establish that the ideal cells 
for cardiac repair should satisfy (but not limited to) the following requirements: easy 
accessibility, being ready-to-use, immune evasion, resistance to stressful conditions, 
prevention of arrhythmias, being free of tumorigenesis or teratogenesis, 
immunomodulation in overactive inflammation, cardiac repair such as neovascularization, 
cardioprotection and anti-apoptosis and cardiomyogenesis. To date, none of the cell 
types that have already been studied could fulfill all the listed requirements. Therefore, 
different cell types with separate advantages have been combined in transplantation to 
complement each other for a better outcome. 
 
Table 1. Advantages and disadvantages of various stem cell origins for heart repair 
Cell types Advantages Disadvantages 
Skeletal muscle-derived cells 
> Myoblasts 
/satellites 
> differentiate into cardiomyocyte-like cells7  
> easy collection through skeletal muscle 
biopsy 
> resistant to oxidative stress9 
> need immunosuppression in allogeneic 
application36,37 
> poor differentiation potential 
> tumorigenic37 
> induce arrhythmias10 
> MDSCs > lack of MHC II expression13 
> multipotent stem cells38 
> more tolerant to oxidative stress9 
> tend to differentiate into cardiomyocytes7  
> rare in tissue and need long-term in 
vitro expansion39  
> indicate tumorigenesis40 
> induce arrhythmias14 
Bone marrow-derived cells 
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Table 1. Advantages and disadvantages of various stem cell origins for heart repair 
Cell types Advantages Disadvantages 
> BMMNCs > quick preparation 
> beneficial paracrine secretion 
> invasive collection 
> components of different cells types 
> need immunosuppression if allogeneic 
application 
> CD34+ BMMNCs 
> CD133+ BMMNCs 
> same as BMMNCs 
> enriched stem cells 
> stronger capacity in improving cardiac 
function25  
> same as BMMNCs 
> immune-suppression is needed 
> relative sensitivity to oxidative stress41 
> induced arrhythmias depending on 
delivery route42 
> BMMSCs > immune evasive43 
> free of tumorigenesis44,45 
> prevent arrhythmias46 
> tolerant to oxidative stress41 
> beneficial effects of immunomodulation, 
neovascularization, cardio-protection through 
abundant paracrine21,47,48 
> long term in vitro expansion 
> chemicals of in vitro cardiomyocyte 
differentiation are toxic23,24 
> lack of in vivo cardiomyogenic evidence 
> STRO3+ MPCs > purified cell constituents 
> same as BMMSCs 
> same as BMMSCs 
> Ixmyelocel-Ts > same paracrine effects as BMMSCs49 
> enlarged immunomodulatory effects50  
> specific technique of in vitro 
expansion51 
> same as BMMSCs 
Adipose tissue-derived cells 
> AT-SVF > minimal invasive tissue collection 
> enriched CD34+ cells 
> similar advantages to BMMNCs 
> mixed population of clear and unclear 
cell types 
> immuno-suppressive therapy is needed 
in allogeneic transplantation 
> ATMSCs > similar as BMMSCs 
> stronger immunomodulatory capacity52,53 
> similar as BMMSCs 
Perinatal tissue-derived cells 
> UCMSCs > No conflict in ethics 
> high concentration MSCs isolated from 
umbilical cord tissue. 
> less immunogenicity than BMMSCs 
> more proliferative 
> more active paracrine secretion 
> same as BMMSCs 
Cardiac endogenous cells 
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Table 1. Advantages and disadvantages of various stem cell origins for heart repair 
Cell types Advantages Disadvantages 
> CSCs/CPCs > cardiomyogenesis54 
> prevent arrhythmias in ischemic heart28,29  
> paracrine secretion for cardiac repair26,27,54 
> tolerant to oxidative stress54  
> immune evasive55 
> cell collection by cardiac tissue biopsy 
> rare inside heart tissue 
> long term in vitro expansion 
 
>CDCs > low immunogenicity56  > same as CSCs/CPCs 
Pluripotent cells 
> ESCs > pluripotent stem cells57 
> more proliferative 
> ethic issues 
> teratogenic30,31 
> less tolerant to oxidative stress 
compared to MSCs58,59 
> less reports and evidence of improving 
cardiac function 
> clinical practice infeasible so far 
> iPSCs > same as ESCs 
> various cell origins 
> same as ESCs 
> long-term laboratory cultivation for gene 
transduction and expansion 
Induced cardiomyocytes 
> iPSC-CMs > various origins > longer preparation than iPSCs 
> immune rejection could be seen even in 
autologous transplantation34  
> tumorigenesis is reported60  
> induced arrhythmias are also 
reported32,33 




Figure 1. Summary of stem cell grade charts 
0-5 grades were given to 10 categories for evaluation of attributes of (A) myoblasts, (B) BMMSCs, (C) ATMSCs, (D) 
UCMSCs, (E) CSCs, and (F) iPSC-CMs in cardiac repair. The higher grade the stem cells can get, the more 




Autologous, allogeneic, and xenogeneic stem cells are tested in animal experiments, 
whilst for human use, only two cell sources are allowed: autologous and allogeneic. To 
date, most completed clinical studies have used autologous stem cells such as BMMNCs, 
ATSVFs and myoblasts. Although there is no concern about acute or chronic immune 
rejection to stem cells from autologous origin, aging, and heart disease could impact the 
quantity and quality of stem cells61. MSCs from aging donors possess impaired 
proliferative and cardioprotective capacity62. The concentration of CD34+ cells in 
BMMNCs from donors over 55 years old is less than half of that found in cells collected 
from healthy donors63,64. In human CSCs, capacities of proliferation and paracrine 
secretion are less influenced by aging65,66, but the concentration of c-kit+ CSCs drops, 
and telomere length is shortened in HF patients66,67. 
 In order to increase the clinical efficacy of heart failure treatment, allogeneic 
immunoprivileged stem cells from young and healthy donors have been utilized in cell 
transplantation68,69. The effectiveness of allo-stem cells for improving cardiac function has 
been confirmed by several clinical trials68,70. Similar cardiac functional improvements 
between syngeneic and allogeneic stem cells were shown in a meta-analysis of large 
animals studies71, but no meta-analyses of clinical trials have been published yet. 
Differences in the cardiac functional improvements between auto- and allo- BMMSCs 
were compared in two clinical trials, but the results were inconsistent. The earlier one 
reported insignificant improvements in the allogeneic group72, while the latter 
demonstrated significant improvements, including increases in LVEF and 6MW distance, 
reduction in MACEs at 1-year follow-up, and efficient immune suppression73. However, 
the characteristic details of the healthy donors in these two trials are unclear. The 
application of allogeneic stem cells has been shown to be feasible and alternative to 
autologous stem cells in HF treatment, but due to insufficient and contradictory published 
data, it is still too early to draw any conclusions.  
Delivery Route 
The delivery strategies of stem cells into the failing heart include direct 
intramyocardial injection (IMI) or intracoronary infusion (ICI) alone, or concurrent 
application with revascularization, transendocardial stem cells injection (TESI) guided by 
an electrical mapping system, intravenous infusion (IVI) or a bio-engineered patch 
embedded with stem cells. The necessity of revascularization has been shown by 
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numerous experiments. Clinical patients under coronary artery bypass grafting (CABG) 
or percutaneous coronary intervention (PCI) have higher survival rates compared to 
patients who are not74,75. Another novel revascularization by transmyocardial laser-made 
channels also increased stem cell retention and up-regulated the expression of 
proangiogenic proteins76. For cell deliveries without surgical revascularizations, the cell 
retention rate is positively correlated with LV function restoration. Several studies proved 
that TESI and direct IMI have better clinical outcomes than ICI and IVI77–79, but the former 
two delivery routes were also reported to be proarrhythmic, possibly because of slowing 
in the conduction area formed by a mass of injected stem cells42,80. 
Cell Dose 
There are an estimated 2-7 billion cardiomyocytes in a healthy human heart, and 
over 50% could be lost after MI and during HF progression81,82, but the numbers of 
transplanted stem cells in either preclinical or clinical trials were never able to compensate 
for the cell loss, especially considering the low cell retention and low survival after 
injection. In large animal experiments, the dose of transplanted stem cells goes typically 
over 100 million, and even 1 billion83. A meta-analysis divided cell doses into four ranges 
(<107, 107-108, 108-109, >109) to explore the correlation between dose escalation and 
LVEF increase. It showed an 8% increase in LVEF at doses over 107 and 6% less than 
107. Clinical trials studying BMMNCs found a positive correlation between CD34+ cell 
concentration and cardiac functional improvements84,85. The dose-dependent effects 
have also been seen with BMMSCs86. For STRO-3+ MPCs, cardiac functional 
improvements increased by dose escalation was confirmed in sheep87, but data from 
clinical trials were hard to interpret. In a high-quality double-blinded randomized control 
clinical trial70, patients with 150 million MPCs showed reverse LV remodeling and reduced 
LVEF, but conversely, patients with 25 million cells had accelerated LV dilation and 
increased LVEF. Patients receiving 75 million MPCs had the highest occurrence of heart 
failure-related major adverse cardiac events (HF-MACEs) and worst performance in the 
6MW test. In the trials of myoblasts, dose escalation does not enhance LVEF 
improvement or increase 6MW distances, but triggers more ventricular arrhythmias88,89. 
Explorations of the dose-response effect of stem cells are not always satisfactory, and 
always depend on proper cell types, indicating the necessity for more well-designed 
studies. 
New strategies to supplement stem cell therapy 
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The application of stem cells for heart failure treatment has been investigated for 
over 20 years. The safety and feasibility of various stem cell types have been repeatedly 
verified in laboratory experiments and clinical trials. Obstacles that hinder the widespread 
application are the following: low retention rate, even less successful engraftments, and 
subsequent cell loss. The cell retention rate was detected to be nearly 5% two hours after 
transplantation, and dropped to only 1% after 24 hours90,91. To increase retention and 
survival rate, biomaterial scaffold embedded with stem cells could be dispatched inside 
the epicardium or injected into target areas92,93. Embedding choices are multiple, which 
could be nearly all cell types94,95, stem cell cocktails, extracellular matrix, and paracrine 
exosomes96. The migration of transplanted cells from the patch into the cardiac tissue 
was observed in rats97. LV dilation was then seen to be reversed, and the ventricular walls 
became thicker. 
Preconditioning of stem cells is another way of increasing cell survival and 
regenerative functions98,99. In dysfunctional hearts, regardless of the etiologies, chronic 
inflammation and ischemia inside heart tissue lead to successive loss of myocardium and 
as well as engrafted stem cells. Preconditioning through hypoxia or repeated ischemia-
reperfusion cycles are the two most common treatments that are used to induce cell 
adaption to severe conditions. Several papers have already reported the increased 
survival rate and enhanced ability to repair infarcted myocardium with preconditioned 
stem cells98,99. 
Another way of increasing stem cell efficacy is cardiac unloading. In the progress of 
heart failure, volume overload caused by weak myocardial contractility causes the 
development of pathological hypertrophy in non-ischemic zones that aggravate 
cardiomyocyte oxidative stress, loss of mitochondrial membrane potential, and 
consequently leads to mitochondrial apoptosis100. Loss of cardiomyocytes, in turn, 
exacerbates volume overload, which perpetuates a vicious circle that eventually leads to 
eccentric hypertrophy. Mechanical assist devices achieving cardiac unloading, combined 
with regenerative therapies, could synergistically break this circle101. Intrinsic stem cells, 
including c-kit+ stem cells and side population cells, significantly increase in the 
myocardium after ventricular unloading102, and cardiomyocytes even show an increase in 
mitosis and cytokinesis103. To study the cell performance in an unloaded heart, 
researchers constructed an animal model through heterotopic transplantation of an 
infarcted heart into a healthy mouse while keeping the orthotopic heart intact104. Cardiac 
stem cells were later injected into this hemodynamically unloading heart. Compared to 
21 
 
the loading control heart, a higher survival rate of stem cells was seen in the unloading 
heart, and more proliferative (Ki67 stained) cells were detected at 21 days post-
transplantation. Therefore, the combination of ventricular assist devices (VADs) and stem 
cells was proposed to be a novel approach to myocardial recovery in which wearing VADs 
could decrease ventricular oxygen consumption and facilitate cardiac repair by stem 
cells105,106. However, a series of randomized control clinical trials that combine LVADs 
with MPCs showed consistently negative results107,108. The proportions of successful 
LVAD weaning at different stages were all similar between the MPC and the sham-control 
groups. The LVEF data from patients, who tolerated the LVAD weaning, did not shown 
the difference either. On the other hand, activated myostatin in patients after LVAD 
implantation raised some concerns that long-term LVAD wearing might cause difficulty in 
removing109. Long-term cardiac disuse causes relative myocardial atrophy that further 
exacerbates this problem110. These findings might partially explain why the combined 
therapy failed in the clinical trials. Nevertheless, despite the similar likelihood of LVAD 
weanings, patients receiving additional MPCs could tolerate a longer LVAD turn-off than 
patients in the control group at the 12-month follow-up107. Therefore, it is still too early to 
confirm the lack of efficacy of stem cells in HF patients with VADs. So far, only trials of 
MPCs were published, and other cell types are still missing for these trials. In addition, 
extracorporeal membrane oxygenation (ECMO) was also tried in combination with stem 
cells but the adherence of stem cells to membrane oxygenator negatively influenced its 
efficacy111. 
In the end-stage of heart failure, irreversible fibrosis leads to ventricular dilation. In 
the third phase of cardiac repair after MI, collagen secretion and scar formation replace 
apoptotic or necrotic cardiomyocytes to keep ventricular integrity; however, they could 
also act as barriers that hamper stem cells from settling down in the ischemic myocardium. 
A study proved that interference with fibrogenesis is beneficial for the restoration of heart 
function after MI112. MiR-29b was the microRNA that targeted several mRNAs encoding 
ECM proteins involved in fibrosis. After transfecting with mimic miR-29b, the fibroblasts 
showed suppressed collagen I and III gene expressions. In the animal models at four 
weeks after inducing MI, heart tissue overexpressing miR-29b had the smallest fibrotic 
area and the thickest ventricular wall in either the infarcted, border or remote area that 
facilitated the iPSCs penetration to a greater extent. Significant vascularization in the miR-
29b pretreated group was confirmed by higher volume and density of newly formed 
vessels. Two-dimensional echocardiography supported these notable in vitro and in vivo 
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data in which rat hearts overexpressing miR-29b had limited LV dilation and restored 
contractility. In the end, the above-mentioned anti-fibrosis, angiogenesis, and subsequent 
improvements in cardiac functions all disappeared in the anti-29b pretreated group. 
Fibrogenesis elimination or collagen digestion seems to be an exciting novel therapeutic 
modality in cardiac repair, further research to fill the existing gaps of knowledge. 
After 20 years of consistent exploration, regenerative therapeutics for heart failure 
are still stagnating in terms of finding the ideal cell or cell-related candidates for 
transplantation. Previously, we summarized the evidence regarding different cell types 
that support cardiac repair in preclinical experiments. Although controversies still exist113, 
a meta-analysis of animal experiments had highlighted the positive effects of stem cell 
therapy79,83, which were also confirmed by several systematic reviews of clinical 
trials114,115. However, the power of that specific meta-analysis was challenged by negative 
results from one individual-level data review116,117. It raised concern that the “in favor of 
stem cells”-result from the meta-analysis might be, in fact, a neutral result. Contradictory 
results from literature-based meta-analyses and individual-based meta-analyses in stem 
cell treatment for acute MI have an impact on the validity of meta-analysis for HF. 
However, in that individual-level study117, most patients received BMMNCs at a dose of 
150 million, while in other literature-based meta-analyses, stem cell types were not limited 
to BMMNCs but also included BMMSCs or other purified cell products. Second, the dose 
of juvenile stem cells should have been estimated at < 5 million in that paper since the 
concentration of real stem cells was quite low in BMMNCs (concentration of CD34+ cells 
in BMMNCs from HF patients versus healthy volunteers: 1.5% versus 3.6%63). The 
heterogeneities within cell types and cell doses suggest that it is still too early to deny the 
benefits of stem cells for patients who underwent MI or had heart failure. We also noticed 
that statisticians or reviewers in general blended cultured stem cells with unfractionated 
cells; therefore, creating insufficient subgrouping. For that reason, in Part I, we will 
subgroup trials based on cell cultivation by separating expanded cells and freshly isolated 
primary cells. More information will be obtained from bone marrow cells, and each cell 
product from this source will be analyzed. Doses of juvenile stem cells will be re-
calculated to determine whether a dose-response effect exists. However, the content in 
Part I mainly focuses on the analyses of stem cells from different origins, and the results 
of more subgroup analyses are beyond the scope of this dissertation. Therefore, they 




Combined with the information provided in the introduction, we constructed our 
hypotheses as follows: 
1. Functional cardiac improvements of stem cells might be very limited in cardiac 
repair. 
2. The robustness of overall positive outcomes might be challenged by 
inappropriate trial designs and execution. 
3. The cultured cells that were modified and optimized in the laboratory might bring 
better cardiac functional improvements compared to isolated primary cells. 
4. Different cell types might cause fluctuations in the effectiveness and efficacy of 




This meta-analysis was registered in PROSPERO with the reference of 
CRD42019118872. 
Definition of reduced ejection fraction 
Systolic heart failure was defined as weak myocardial contractility and failed to meet 
the body’s demands. Patients presenting with heart failure symptoms, including dyspnea, 
fatigue, reduced exercise capacity, and edema in the legs, ankles and feet, etc., also 
supported by ultrasonic and radiological examination with LVEF less than 40%, were 
diagnosed as HFrEF. A new category of heart failure, Heart Failure with Mid-Range 
Ejection Fraction (HFmrEF, LVEF 40%-49%), was introduced in 2016118. In this meta-
analysis, we included heart failure patients with reduced ejection fraction (HFrEF and 
HFmrEF). 
Outcome measures 
Primary outcomes include all-cause mortality for safety evaluation and change in 
LVEF from baseline for efficacy. The definition of all-cause mortality was a composite of 
all causes of mortality, heart transplantation, and LVAD implantation (Table 2).  
Secondary outcomes include heart failure-related major adverse cardiovascular 
events (HF-MACEs) and serious adverse events (SAEs) for safety, left ventricular end-
diastolic diameter/ left ventricular end-diastolic volume/ left ventricular end-diastolic 
volume index (LVEDD/ LVEDV/ LVEDVI), brain natriuretic peptide/ N-terminal brain 
natriuretic peptide (BNP/ NT-proBNP), six-minute walk distance (6MW distance)/ walking 
speed, New York heart association functional status (NYHA functional status), and quality 
of life for efficacy. HF-MACEs in this meta-analysis are defined as a composite of nonfatal 
stroke, nonfatal myocardial infarction, cardiac death, decompensated HF, and persistent 
ventricular arrhythmias. LVEDD, LVEDV, and LVEDVI were measured to quantify the 
extent of LV remodeling and dilation. BNP and NT-proBNP were put together to assess 
the severity of cardiac overload, and 6MW distance in addition to walking speed were 
used to evaluate exercise ability. 
Retrieving strategies and study selection 
Publications and registered clinical trials were retrieved from Medline, EMBASE, and 
clinicaltrials.gov in August 2018. The search formula was (heart failure OR myocardial 
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ischemia OR heart infarction OR ischemic heart disease) AND (stem cell transplantation 
OR transplantation). In the PubMed database, the filter for article types was applied so 
that only clinical trials were shown in the results.  
The inclusion criteria were as follows:  
-- clinical trials 
-- adult patients (>18 years old) 
-- HF secondary to ischemic or non-ischemic reason: LVEF<50%, NYHA II-IV. 
-- studies reporting primary outcomes 
-- follow-up >3 months after transplantation 
-- publications written in English 
Exclusion criteria: 
-- review, preclinical experiments, case reports 
-- juvenile patients 
-- HFrEF due to Chagas disease 
-- patients receiving LVAD implantations 
-- publications written in non-English languages 
-- papers that are not accessible 
For further meta-analysis, only randomized controlled trials (RCTs) were included. 
Notably, in patients that underwent LVAD implantation, most deaths were attributed 
to LVAD dysfunctions, pump thrombus, multi-system organ failure, and sepsis that are 
irrelevant to cell therapy. The wearing of LVAD unloading left ventricles also impacts the 
accuracy of graphic assessments. Therefore, trials of patients who underwent LVAD 
implantations were excluded.  
Calculation of stem cell numbers 
Since subgroup analysis based on cell doses was expected, the numbers of stem 
cells were then calculated by the expressions of specific biomarkers. For myoblasts, cell 
numbers were calculated by their expression of CD56 or desmin. For BMMNCs and 
ATSVFs, stem cell numbers were estimated by the expression of CD34 biomarkers 
(explained in the Discussion section). As shown in Table 3 and other clinical records119,120, 
the concentrations of CD34+ cells in BMMNCs from heart failure patients were reported 
from 0.7% to 3%. However, not all the BMMNC trials had published detail concentrations 
or amounts of CD34+ cells. Therefore, we settled those cell concentration that missing in 
the papers as 1% (The purpose of this rough estimate was only to divide those trials into 
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four subgroups of ranges of increasing cell doses. In Table 3, the estimations of CD34+ 
cell numbers were shown in digital intervals instead of specific numbers, for instance <1, 
1-10, 10-100, etc. Meanwhile, the results based on the cell doses were not reported and 
discussed but only listed in Table 5 as supplementary data). In trials with concentrated 
cell products such as CD34+, CD133+, or ALDH+ cells, cells were immunoselected and 
highly purified by their biomarkers, so the concentraions or detail numbers of stem cells 
were all needed and published in the papers that we can use directly. Cultured cells such 
as BMMSCs or MPCs were already purified during in vitro expansion, so no extra 
calculation was needed. Additionally, stem cells in Ixmyelocel-T cells were calculated by 
the percentage of CD93+ cells. 
Subgroup analyses to detect possible sources of heterogeneities 
Heterogeneous values were expected in our meta-analysis due to the diversity of 
study designs. Patient data were divided into subgroups based on clinical differences to 
help researchers investigate the origin of heterogeneities: 
> Cell cultivation: primary cells after isolation and cultured cells after in-vitro 
cultivation. 
> Cell origin: skeletal muscle-derived stem cells, BM-derived stem cells, AT-derived 
stem cells, perinatal stem cells, cardiac endogenous stem cells. 
> BM-derived cell line: BMMNCs and selected CD34+, CD133+, ALDH+ cells, 
BMMSCs, STRO-3+ MPCs, BM-derived cardiopoietic stem cells, Ixmyelocel-T cells. 
> HF type: heart failure secondary to myocardial ischemia, dilated cardiomyopathy. 
> Cell source: autologous stem cells from patients, allogeneic sources from 
volunteers. 
> Delivery route: IVI, ICI, IMI, cell delivery after CABG, TESI, bioengineered cell 
sheets. The intervention of revascularization referred to surgical CABG or PCI. 
> Dose escalation of estimated stem cells: <1 million, 1-10 million, 10-100 million, ≥
100 million. Patients were stratified into four groups according to numbers of stem cells: 
<1 million, 1-10 million, 10-100 million and ≥100 million. 
Data extraction 
Data on primary and secondary outcomes were extracted by two reviewers. In the 
case of data extraction from multi-arm trials with different interventions, to avoid repeating 
input, the number of participants in the control group was divided and equally distributed 
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among the different comparisons. This data manipulation was only necessary when 
multiple comparisons were placed in one single analysis. 
By eliminating bias caused by baseline imbalance and diverse imaging techniques, 
the change from baseline is more accurate; however, many of the investigators reported 
data as mean at the endpoint, but without change from baseline. However, the mean 
change from baseline could be easily calculated from the mean at the endpoint, according 
to the Cochrane handbook, de Jong121, and Hristov et al122. Therefore, in this meta-
analysis, the change from baseline of continuous variables such as LVEF, LVEDV was 





In the papers which provided all the necessary data, corr was calculated according 









The mean corr values in LVEFs was calculated to be 0.76 and 0.62 in short- and 
long-term follow-ups, 0.91 and 0.97 in LVEDV, but the calculation was not feasible for 
other variables due to insufficient data. The estimated mean and SD of change were then 
filled. 
In case that data combination was needed, the data were combined according to the 
















Meta-analysis was performed in Stata15 and RevMan v5.3 for double checking. 
Characteristic details, including data type, data unit, data source, and effect measures in 
the meta-analysis are listed in Table 2.  
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Risks of bias were evaluated based on RoB2 (a revised Cochrane risk-of-bias tool 
for randomized trials123). The graph and summary were automatically generated by the 
tool. Publication biases were assessed by funnel plots and Egger’s test. P value >0.05 
indicates no evidence of any small-study effect. 
Since heterogeneity was expected and found in the pre-study, random effect and 
inverse variance models were used to control unobserved heterogeneity. Data are shown 
as mean [95% confidence intervals]. I2 and Tau2 were utilized to quantify the extent of 
heterogeneities, in which I2>50% stood for substantial heterogeneity, and p<0.05 (from Q 
test for heterogeneity) indicated statistically significant heterogeneity. Sensitivity and 
subgroup analyses were conducted based on trial quality, clinical and methodological 
differences including cell cultivation, cell origins, HF types, cell sources, delivery routes, 
and cell doses, to identify the sources of heterogeneities and their influence on the 
effectiveness and efficacy of stem cell therapy for HF.  
 
Table 2. Data characteristics of primary and secondary outcomes in meta-analysis 
Outcomes Data type Data unit Data source Effect measures 
Primary outcomes 













change from baseline 
mean at endpoints 




change from baseline 
mean at endpoints 






change from baseline 
mean at endpoints 
std. mean difference 
NYHA continuous - 
change from baseline 
mean at endpoints 
mean difference 
quality of life continuous - 
change from baseline 









incidence at endpoints risk ratio 




The workflow of this meta-analysis is depicted in Figure 2A.  
In total, 1,810 records were retrieved from Medline and EMBASE, and 84 trials that 
were registered at clinicaltrial.gov. 42 studies were included according to the inclusion 
and exclusion criteria (Figure 2B). 2,699 patients were included after randomization, 136 
excluded before the intervention, and 121 lost during follow-up. Common reasons for 
exclusion before transplantation were withdrawal of consent, off-specification of cell 
products, death during waiting, rare machine malfunction, and ineligibility of patients. 
Loss during follow-up might be due to medical device implantation, undefined withdrawal, 
and so on. 
Characteristics of the 42 included RCTs are described in Table 3. Figure 3A-B 
summarize the methodological quality of enrolled studies through the Cochrane risk-of-
bias tool. Since high heterogeneities were found in the overall results of LVEF change 
(high I2 in Figure 4), sensitivity analysis, which separated trials by different qualities in 
this meta-analysis, was performed to determine whether low trial qualities impacted the 
outcome robustness. An extra clarification is need here: as seen in Figure 3A, selection 
bias occurs in two ways, inadequate generation of randomized sequence and 
foreknowledge of treatment assignment. The breaking of blindness in either 
randomization or allocation would include unrepresentative samples into the trials. 
Therefore, in the sensitivity analysis based on selection bias, we grouped all the trials 
together into low risk group if they have low risks in both randomization and allocation, 
and assign the rest to high/unclear group. In Figure 3C-F, trials that did not employ 
sufficient methods of randomization and blinding during operation (high/unclear risk in 
selection bias and performance bias, respectively) had significantly better outcomes of 
LVEF increase than trials that utilized more appropriate randomization and blinding 
methods. However, the quality of blindness during follow-up examination (risk of detection 
bias) did not significantly influence the size of mean difference in LVEF change (Figure 
3G-H). 
Overall effects on primary and secondary outcomes 
Details of group sizes, p values of effects, I2 for heterogeneity, effect sizes of 
comparisons, and corresponding 95% confidence intervals are provided in Table 4. 
In Figure 4A-B, the favorability of cell therapy in reducing mortality of HF patients 
was not shown within 12-month observation (RR=0.80 [0.45, 1.43], p=0.45, I2=0%) but 
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was seen over 12-month follow-up (RR=0.71 [0.54, 0.93], p=0.01, I2=7%). A 2.88% 
increase of LVEF among stem cell groups over controls was demonstrated at short-term 
follow-up ([1.70, 4.06], p<0.00001, I2=83.7%) (Figure 4C), but slightly decreased to 2.33% 
[0.64, 4.02] after long-term follow-up (p=0.07, I2=83.8%) (Figure 4D). High 
heterogeneities were shown with LVEF data at both short-term and long-term follow-ups, 
implying significant clinical differences among those trials. Meanwhile, funnel plots and 
Egger’s tests for small-study effects based on primary outcomes showed no sign of 
publication bias in the meta-analysis (Figure 5). 
Detail effect sizes of overall cell therapies on secondary clinical outcomes are shown 
in Table 4. The incidence of MACEs and SAEs were significantly reduced by stem cells 
at long-term follow-up. In LV remodeling, the standardized mean difference between cell 
therapy and control suggested benefits of stem cells for ameliorating left ventricular 
dilation. In the short term after transplantation, LV sizes in cell groups became smaller 
than controls (-0.20 [-0.36, -0.03], p=0.02), and over a long-term period the extent of LV 
size reduction went even further (-0.34 [-0.54, -0.13], p=0.001). Moreover, the benefits of 
stem cells also included improvements in exercise capacity. Patients receiving stem cells 
could walk further or faster than patients in control. The beneficial effects were also 
extended over a long-term time period (std. mean difference from mean at endpoint: 0.55 
[0.17, 0.94] <12 months and 0.85 [0.07, 1.64] ≥12 months). Applying the New York Heart 
Association classification to HF symptoms, no favorability of cell therapy was detected in 
the short term, but over 12 months patients in the cell groups had a significantly 
decreased NYHA class (-0.46 [-0.74, -0.17], p=0.002) compared to controls indicating 
better general functional status among them. For other analyses, including life quality 
(MLHFQ) and biomarkers reflecting HF severity (BNP/NT-proBNP), no statistical 
difference was observed between cell therapy and control.  
Discrepancies in outcomes due to cell cultivation techniques 
Within 12 months, no differences in primary outcomes were seen between primary 
and cultured cells. No advantage of either stem cell types was present in regard to 
mortality, but increases in LVEF were shown in both categories (Figure 6A, C). No sign 
of LV-size shrinking in either primary or cultured cell group compared to control patients 
was shown (Figure 6E), but results were slightly in favor of primary cells in relation to 
NYHA class improvement (Figure 6G). 
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Over 12 months, the risk ratio in mortality between patients in primary cell group and 
control group is 68% ([47%, 97%], p=0.03), a 32% decrease in risk of death after primary 
cells infusion (Figure 6B). Meanwhile a 3.05% [1.00, 5.10] higher increase in LVEF with 
primary cell transplantation (p=0.004) (Figure 6D). Freshly isolated primary cells also 
decreased LV sizes (std. Mean difference-change from baseline: -0.44 [-0.75, -0.13], 
p=0.005) (Figure 6F). Contrarily, in vitro expanded cells had a similar effect of increasing 
LVEF as primary cells at short-term follow-up (2.92% [0.86, 4.99], p=0.005) (Figure 6C). 
But over 12 months this effect became insignificant that from Figure 6D their horizontal 
line of confidential intervals was seen to cross the vertical dotted no-effect line. Moreover, 
it was also found in the long-term follow-up that cultured cells could also help in relieving 
HF symptoms. The patients who received cultured stem cells had lower NYHA classes 
compared to the control groups (Mean difference-mean at the endpoint: -0.73 [-1.25, -
0.2], p=0.007) (Figure 6H). 
Discrepancies in outcomes due to cell origins 
42 RCTs were sub-grouped based on diverse cell origins: skeletal muscle-derived 
stem cells, BM-derived stem cells, AT-derived stem cells, and perinatal stem cells (Figure 
7, Table 4). 
 At short-term follow-up, meta-analysis failed to find any beneficial effects from 
myoblasts on cardiac repair, either in increasing LVEF (-0.03[-2.08, 2.02], p=0.98, I2=0%, 
Figure 7C), or reducing mortality (2.27 [0.60, 8.62], p=0.23, Figure 7A) or by any 
improvements in the other outcomes (Figure 7E, G). Over long-term follow-up, myoblasts 
were only found to improve NYHA functional status significantly (mean difference: -1.30 
[-1.75, -0.85], p<0.00001, Figure 7H). Conversely, BM-derived cells proved their 
effectiveness in cardiac recovery, having a short-term advantage of increasing LVEF by 
3.29% (95%CI: [2.03, 4.54], p<0.00001, Figure 7C), and also a long-term effect of 2.66% 
(95%CI: [0.81, 4.51], p=0.005, Figure 7D) over controls. Other capacities as slowing 
down the progression of LV dilation, decreasing mortality, the incidence of SAEs at short-
term follow-up, and a long-term decrease in NYHA class, are listed in Table 4. Perinatal 
stem cells, specifically UCMSCs in the meta-analysis, showed the potential to be a better 
cell choice for heart recovery. Peinatal stem cells increased more LVEF than BM-derived 
cells. The effect size after the short-term follow-up was 6.48% [2.84, 10.15] (p=0.0005) 
and remained over 5% after the long-term follow-up (5.22 [0.84, 9.6], p=0.02). Moreover, 
they seemed to be more efficient in reversing LV dilation (Figure 7E). However, as shown, 
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only two included trials used perinatal stem cells, and the robustness of these results is 
not strong enough to draw any conclusions. Similarly, the same problem exists with AT-
derived cells. Unfortunately, insufficient data from these two different cells is difficult to 
supplement in a short period because the number of relevant registered or undergoing 
RCTs is very few. 
The influence of other methodological and clinical differences on stem cell efficacy, 
such as cell types, HF types, cell sources, surgical interventions, and cell doses, was also 







Figure 2. Visualizations of meta-analysis and study retrieval 
A) Workflow of meta-analysis 




Table 3. Characteristics of 42 included randomized controlled trials (RCTs) for meta-analysis 
Study identifier Group size HF type Cell source Cell type 
Nucleated cells  
(Million) Cell purity 
























15-20% FBS TESI 3, 6, 12 
Duckers 2011126 
SEISMIC 47 ischemic autologous myoblasts 596±194 
CD56+: 
57.2±23.9% >100 15-20% FBS IMI 3, 6 
Menasche 200888 
MAGIC 120 ischemic autologous myoblasts - 89% 
400 
800 FBS CABG+IMI 6 
Povsic 201189 23 ischemic autologous myoblasts 400 800 - 
400 
800 FBS TESI 6 
BM-derived cells 
Ang 2008127 63 ischemic autologous BMMNCs IMI arm:84±56 ICI arm:115±73 - 
CD34+CD117+ 
IMI arm: 0.142±0.166 
ICI arm: 0.245±0.254 
 CABG+ICI/IMI 6 
Assmus 2013128 





- 1-10  Shockwave+ICI 4 
Bartunek 2013129 









TESI 6, 2 years 
Bartunek 2017130 

















Table 3. Characteristics of 42 included randomized controlled trials (RCTs) for meta-analysis 
Study identifier Group size HF type Cell source Cell type 
Nucleated cells  
(Million) Cell purity 





























60 non-ischemic autologous BMMNCs 216±221.8 - CD34+: 4.91±2.75  G-CSF+ICI 3, 12 
Heldman 2014134 




BMMNCs: 200 - 
BMMSCs: >100 
BMMNCs: 1-10 20% FBS TESI 6, 12 
Hendrikx 200684 23 ischemic autologous BMMNCs 60.25±31.35 CD34
+: 
1.42±0.99% <1  CABG+IMI 4 
Henry 2014135 








1-10 20% FBS IMI/TESI 12 




arm of MiHeart 
160 non-ischemic autologous BMMNCs 236±271 
CD34+: 2.26% of 
mean 
CD133+: 0.03% of 
mean 
1-10  ICI 6, 12 
Mathiasen 2015138 




TESI 1, 3, 6 
Maureira 2012139 14 ischemic autologous BMMNCs 342±41 CD34
+: 3±1% 
CD73+: 0.2±0.6% 10-100  CABG+IMI 1, 6 
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Table 3. Characteristics of 42 included randomized controlled trials (RCTs) for meta-analysis 
Study identifier Group size HF type Cell source Cell type 
Nucleated cells  
(Million) Cell purity 








Cardio133 60 ischemic autologous 
BM-derived 
CD133+ cells - CD133
+: 73.6% CD133
+: 5.1(3.0-9.1) 
medium (IQR)  CABG+IMI 6 
Noiseux 2016141 
IMPACT-CABG 33 ischemic autologous 
BM-derived 
CD133+ cells - 63.3±15.5% 
CD133+CD34+CD45+: 
6.5±3.1  CABG+IMI 6 






- 70% medium of CD34+: 22  CABG+IMI 1, 3, 6 
Patel 2015143 
REVIVE 60 both autologous 
concentrated 
BMMNCs 3700±900 - CD34
+: 39.4  ICI 1, 3, 6, 12 
Patel 2016143 




CD90+: 1-10 20% FBS TESI 3, 6, 12 





CD34+: 10-100  CABG+IMI 12 
Perin 201163 
FOCUS-HF 30 ischemic autologous BMMNCs 484.1±313 CD34+: 1.5±0.4% 1-10  TESI 6 
Perin 2012a145 




2.94±1.31 - ALDH+: 2.37±1.31  TESI 6 
Perin 2012b85 
FOCUS-CCTRN 92 ischemic autologous BMMNCs 100 
CD34+: 2.6% 
CD133+: 1.2% 1-10  TESI 6 








10% FBS TESI 3, 6, 12 
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Table 3. Characteristics of 42 included randomized controlled trials (RCTs) for meta-analysis 
Study identifier Group size HF type Cell source Cell type 
Nucleated cells  
(Million) Cell purity 














ischemic autologous BMMNCs 106±43 CD34
+: 1.5±0.7% 1-10  transthoracic+IMI 3, 6, 12 
Santoso 2014148 
END-HF 28 ischemic autologous BMMNCs - - 
CD34+: 2.4±1.2/ml 
8-15 injections 0.1ml per 
injection 




ischemic autologous BMMNCs 168±96 - CD34
+: 2.7±1.5  ICI 6, 3years 
Steinhoff 2017150 
PERFECT 82 ischemic autologous 
BM-derived 
CD133+ cells - - 2.29±1.42  CABG+IMI 6 
Trifunovic 2015151 30 ischemic autologous BMMNCs 70.7±32.4 - CD34
+: 3.96±2.77 
CD133+: 2.65±1.71  CABG+IMI 2, 6, 12 






- - CD34+: 113±26  G-CSF+ICI 1, 5 years 












ICI 3, 12 
Zhao 2008154 36 ischemic autologous BMMNCs 659±512 - 10-100  CABG+IMI 1, 3, 6 
Adipose-derived stem cells 
Henry 2017155 
ATHENA 31 ischemic autologous AT-SVF 40±9 - -  TESI 




Table 3. Characteristics of 42 included randomized controlled trials (RCTs) for meta-analysis 
Study identifier Group size HF type Cell source Cell type 
Nucleated cells  
(Million) Cell purity 








PRECISE 27 ischemic autologous AT-SVF 42 CD34





ischemic allogeneic UCMSCs - - 1/kg 
10% AB 
plasma IVI 12 
Zhao 201568 59 non-ischemic allogeneic UCMSCs - - - 10%FBS ICI 1, 6 



















Figure 3. Quality assessments of 42 RCTs 
(A) Risk of bias graph. (B) Risk of bias summary. Influences of (C&D) selection 
bias in LVEF increase at short-term (p=0.1) and long-term follow-up (p=0.004), 
(E&F) performance bias at short-term (p<0.001) and long-term follow-up 
(p=0.0003), and (G&F) detection bias at short-term follow-up (p=0.43) and long-
term follow-up (p=0.49). 
N beneath the grid name on the y-axis indicates the number of comparisons 
enrolled in that subgroup, and that more than one comparison could be 
extracted from one study. 
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Figure 4. Overview of primary outcomes 
Results of primary outcomes of mortality (A&B) and LVEF change from baseline (C&D) were shown at both short-
term and long-term follow-ups.  




A. Funnel plot of mortality (<12 months) 
 
B. Funnel plot of mortality (≥12 months) 
 
C. Egger’s test for mortality (<12 months) 
 
D. Egger’s test for mortality (≥12 months) 
 
E. Funnel plot of LVEF change (<12 months) 
 
F. Funnel plot of LVEF change (≥12 months) 
 
G. Egger’s test for LVEF (<12 months) 
 
H. Egger’s test for LVEF (≥12 months) 
 
Figure 5. Publication bias assessments in primary outcomes 
Funnel plots indicate fitted regression lines (orange) and egger’s test for small-study effects (A, C) of mortality at 
short-term and (B, D) long-term follow-ups. The same assessments were performed on LVEF change at short-term 
(E, G) and long-term (F, H) follow-ups. Both oblique regression lines in LVEF change plots (E&F) indicate lacking 
positive results for stem cell therapy, despite no significance in Egger’s tests. 
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Figure 6. Summary of subgroup analyses in primary and in vitro cultured cells. 
(A&B) Mortality at short- and long-term follow-ups; (C&D) LVEF increase from baseline at short- and long-term follow-
ups; (E&F) left ventricular size; (G&H) NYHA functional status. 
N beneath the grid name on the y-axis indicates the number of comparisons enrolled in that subgroup, and that more 
than one comparison could be extracted from one study. 
.ch: data of change from baseline 
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Figure 7. Summary of subgroup analyses in different cell origins 
(A&B) mortality; (C&D) LVEF increase from baseline; (E&F) left ventricular size; (G&H) NYHA functional status 
N beneath the grid name on the y-axis indicates the number of comparisons enrolled in that subgroup, and that more 
than one comparison could be extracted from one study. 
.ch: data of change from baseline 
.m: data of mean at the endpoint 
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Table 4. Summary of results of all clinical outcomes in overall pooled analysis and subgroup analysis by cell origins 
Number of 
comparisons[participants] 























Mean at endpoint 
Quality of life 
Change from 
baseline 
Quality of life 
Mean at endpoint Mortality MACEs SAEs 
Overall 
<12 months 
42[1773] 30[1306] [27]930 4[193] 7[232] 11[516] 14[677] 12[477] 20[686] 10[317] 7[334] 18[857] 8[466] 13[870] 
<0.00001 0.20 0.02 0.16 0.79 0.03 0.005 0.07 0.06 0.61 0.34 0.45 0.96 0.31 
84% 64% 30% 95% 0% 85% 81% 87% 97% 39% 88% 0% 0% 7% 
2.88 [1.70, 4.06] -0.13 [-0.33, 0.07] -0.20 [-0.36, -0.03] -1.03 [-2.47, 0.42] 0.04 [-0.23, 0.30] 0.65 [0.08, 1.21] 0.55 [0.17, 0.94] -0.32 [-0.67, 0.03] -0.38 [-0.78, 0.01] 1.95 [-5.58, 9.47] -7.75 [-23.61, 8.11] 0.80 [0.45, 1.43] 1.01 [0.72, 1.42] 1.15 [0.86, 1.56] 
>12 months 
26[1023] 18[837] 18[618] 2[71] 5[106] 6[232] 8[361] 8[242] 13[388] 8[301] 5[249] 24[1502] 12[571] 7[364] 
0.007 0.001 0.15 0.29 0.12 0.08 0.03 0.002 0.006 0.54 0.44 0.01 0.04 0.03 
84% 48% 0% 99% 0% 87% 90% 68% 91% 64% 92% 7% 0% 8% 








27[1071] 19[806] 19[716] 4[193] 4[246] 8[415] 6[347] 8[390] 15[526] 4[176] 4[246] 13[566] 6[329] 8[400] 
0.0001 0.3 0.13 0.16 0.41 0.07 0.1 0.05 0.15 0.41 0.58 0.69 0.6 0.75 
82% 23% 58% 95% 88% 92% 89% 90% 97% 42% 92% 0% 0% 27% 
2.86 [1.39, 4.33] -0.15 [-0.44, 0.14] -0.12 [-0.28, 0.04] -1.03 [-2.47, 0.42] -0.32 [-1.10, 0.45] 0.70 [-0.06, 1.45] 0.59 [-0.11, 1.28] -0.46 [-0.91, -0.01] -0.35 [-0.82, 0.12] -5.05 [-17.09, 6.99] 
-7.22 [-32.83, 
18.40] 0.85 [0.39, 1.88] 0.90 [0.61, 1.33] 0.96 [0.75, 1.23] 
≥12 months 
15[576] 9[445] 11[481] 2[71] 1[26] 5[207] 4[224] 3[132] 8[299] 4[220] 3[196] 17[898] 7[267] 4[199] 
0.004 0.005 0.19 0.29 0.36 0.1 0.13 <0.00001 0.1 0.16 0.62 0.03 0.97 0.03 
82% 38% 19% 99% - 90% 95% 21% 93% 70% 94% 14% 0% 0% 








15[702] 11[500] 8[214] - 5[136] 3[101] 8[330] 4[87] 5[160] 6[141] 3[88] 5[291] 2[137] 5[470] 
0.005 0.37 0.21 - 0.43 0.008 0.02 0.53 0.05 0.05 0.18 0.53 0.28 0.06 
87% 73% 3% - 91% 0% 69% 0% 76% 6% 24% 18% 0% 58% 
2.92 [0.86, 4.99] -0.10 [-0.32, 0.12] -0.28 [-0.73, 0.16] - -0.57 [-2.00, 0.85] 0.56 [0.14, 0.97] 0.52 [0.07, 0.97] -0.09 [-0.36, 0.18] -0.46 [-0.92, -0.00] 7.58 [-0.10, 15.26] -8.07 [-19.78, 3.63] 0.73 [0.27, 1.97] 1.48 [0.72, 3.03] 1.72 [0.97, 3.04] 
≥12 months 
11[447] 9[392] 7[137] - 4[80] 1[25] 4[137] 5[110] 5[89] 4[81] 2[53] 9[624] 6[321] 3[165] 
0.26 0.11 0.67 - 0.27 0.41 0.08 0.12 0.007 0.35 0.48 0.34 0.01 0.78 
65% 58% 0% - 12% - 0% 78% 67% 15% 69% 0% 0% 45% 
1.17 [-0.87, 3.21] -0.23 [-0.52, 0.05] -0.09 [-0.50, 0.32] - -0.30 [-0.84, 0.23] 0.35 [-0.47, 1.17] 0.32 [-0.04, 0.68] -0.40 [-0.90, 0.11] -0.73 [-1.25, -0.20] 4.34 [-4.73, 13.42] -6.68 [-25.28, 11.92] 0.80 [0.51, 1.26] 0.73 [0.53, 0.99] 0.93 [0.55, 1.56] 
Myoblast 
<12 months 
3[127] 2[32] 2[32] 0[0] 0[0] 1[38] 1[38] 0[0] 2[52] 1[20] 2[60] 3[157] 2[137] 4[180] 
0.98 0.35 0.95 - - 0.15 0.76 - 0.05 0.05 0.05 0.23 0.28 0.24 
0% 3% 0% - - - - - 80% - 6% 0% 0% 0% 
-0.03 [-2.08, 2.02] -0.35 [-1.08, 0.39] -0.35 [-1.08, 0.39] - - 0.49 [-0.18, 1.16] 0.10 [-0.56, 0.76] - -0.79 [-1.57, -0.00] 11.50 [-0.04, 23.04] 
-13.11 [-26.45, 
0.22] 2.27 [0.6,8.62] 1.48 [0.72,3.03] 1.28 [0.85, 1.93] 
>12 months 
1[9] 1[6] 2[31] 0[0] 0[0] 0[0] 0[0] 1[25] 2[30] 0[0] 1[25] 2[30] 0[0] 1[23] 
0.85 0.47 0.77 - - - - p<0.00001 p<0.00001 - 0.009 - - 0.32 
- - 0% - - - - - 0% - - - - - 
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Table 4. Summary of results of all clinical outcomes in overall pooled analysis and subgroup analysis by cell origins 
Number of 
comparisons[participants] 























Mean at endpoint 
Quality of life 
Change from 
baseline 
Quality of life 
Mean at endpoint Mortality MACEs SAEs 
-1.25 [-14.06, 
11.56] 0.66 [-1.15, 2.48] 0.11 [-0.61, 0.82] - - - - -1.30 [-1.75, -0.85] -1.06 [-1.43, -0.70] - 
-15.00 [-26.18, -
3.82] - - 1.47 [0.69, 3.14] 
BM-derived 
<12 months 
36[1541] 27[1244] 23[803] 4[193] 7[304] 10[478] 12[589] 11[449] 16[581] [9]297 4[246] 13[610] 5[298] 7[369] 
<0.00001 0.12 0.07 0.16 0.74 0.04 0.02 0.1 0.09 0.98 0.58 0.27 0.41 0.88 
83% 66% 10% 95% 80% 90% 78% 88% 97% 33% 92% 0% 0% 34% 
2.89 [1.61, 4.17] -0.17 [-0.38, 0.04] -0.15 [-0.30, 0.01] -1.03 [-2.47, 0.42] -0.10 [-0.68, 0.48] 0.66 [0.04, 1.29] 0.48 [0.09, 0.87] -0.33 [-0.71, 0.06] -0.38 [-0.83, 0.07] 0.08 [-7.98, 8.14] -7.22 [-32.83, 18.40] 0.66 [0.31,1.39] 0.84 [0.56,1.27] 0.98 [0.73, 1.31] 
>12 months 
24[986] 16[803] 15[559] 2[71] 4[78] 6[232] 8[361] 6[189] 9[306] 8[301] 3[196] 20[1415] 10[514] 6[341] 
0.01 0.0008 0.22 0.29 0.5 0.29 0.35 0.02 0.02 0.54 0.62 0.03 0.09 0.002 
85% 51% 0% 99% 0% 87% 90% 49% 90% 64% 94% 14% 0% 0% 
2.26 [0.50, 4.01] -0.37 [-0.58, -0.15] -0.11 [-0.28, 0.07] -7.90 [-22.63,6.83] -0.17 [-0.67, 0.33] 0.75 [-0.08, 1.57] 0.85 [0.07, 1.64] -0.34 [-0.63, -0.05] -0.58 [-1.08, -0.09] -3.44 [-14.39,7.51] -9.20 [-45.39, 7.00] 0.71 [0.53, 0.96] 0.76 [0.55,1.04] 0.69 [0.54, 0.88] 
AT derived 
<12 months 
1[27] 1[27] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 1[25] 0[0] 0[0] 1[31] 1[31] 1[31] 
0.42 0.53 - - - - - - 0.88 - - 0.23 0.41 0.52 
- - - - - - - - - - - - - - 
0.73 [-1.04, 2.50] -0.35 [-1.08, 0.39] - - - -  - -0.04 [-0.58, 0.50] - - 5.83 [0.33, 104.22] 1.65 [0.50,5.42] 0.82 [0.45, 1.49] 
>12 months 
0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 1[24] 0[0] 0[0] 1[27] 1[27] 0[0] 
- - - - - - - - 0.71 - - 0.28 0.16 - 
- - - - -   - - - - - - - 
- - - - - -  - -0.11 [-0.69, 0.47] - - 0.43 [0.09, 2.00] 0.29 [0.05,1.62] - 
Perinatal 
<12 months 
2[78] 1[28] 2[78] 0[0] 2[78] 0[0] 1[50] 1[28] 1[28] 0[0] 1[28] 1[59] 0[0] 0[0] 
0.0005 0.36 0.03 - 0.2 - <0.00001 0.18 0.52 - 0.98 0.09 - - 
67% - 55% - 96% - - - - - - - - - 
6.48 [2.81, 10.15] -0.35 [-1.08, 0.39] -0.82 [-1.54, -0.10] - -1.86 [-4.74, 1.01] - 1.90 [1.22, 2.58] -0.26 [-0.64, 0.12] 0.14 [-0.29, 0.57] - 0.21 [-16.27, 16.69] 0.28 [0.06, 1.22] - - 
>12 months 
1[28] 1[28] 1[28] 0[0] 1[28] 0[0] 0[0] 1[28] 1[28] 0[0] 1[28] 1[30] 1[30] 0[0] 
0.02 0.92 0.1 - 0.07 - - 0.04 0.9 - 0.64 1 0.19 - 
- - - - - - - - - - - - - - 
5.22 [0.84, 9.60] 0.04 [-0.70, 0.78] -0.64 [-1.40, 0.12] - -0.71 [-1.48, 0.06] - - -0.37 [-0.71, -0.03] -0.03 [-0.50, 0.44] - 4.14 [-13.43, 21.71] 1.00 [0.07, 14.55] 0.25 [0.03,1.98] - 
































Mean at endpoint 
quality of life 
Change from 
baseline 
quality of life 
Mean at endpoint mortality MACEs SAEs 
BMMNCs 
<12 months 
20[832] 13[588] 14[546] 3[140] 3[192] 7[370] 6[341] 6[316] 11[416] 5[212] 4[246] 7[362] 3[188] 3[183] 
<0.00001 0.64 0.06 0.48 0.3 0.27 0.07 0.007 0.15 0.28 0.58 0.28 0.66 0.22 
61% 72% 21% 94% 88% 87% 88% 65% 97% 25% 92% 0% 21% 56% 
3.33 [2.06, 4.61] -0.08 [-0.42, 0.26] -0.20 [-0.40, 0.01] -0.58 [-2.19, 1.03] -0.49 [-1.40, 0.42] 0.34 [-0.26, 0.95] 0.64 [-0.04, 1.33] -0.38 [-0.65, -0.10] -0.37 [-0.87, 0.13] -5.31 [-14.94, 4.31] 
-7.22 [-32.83, 
18.40] 0.62 [0.27, 1.46] 0.87 [0.45, 1.66] 0.58 [0.24, 1.39] 
≥12 months 
14[539] 8[400] 11[489] 1[26] 1[26] 4[162] 4[224] 3[132] 7[283] 4[220] 3[196] 13[668] 6[240] 3[89] 
0.02 0.006 0.17 0.23 0.36 0.26 0.13 <0.00001 0.07 0.16 0.62 0.27 0.66 0.45 
81% 14% 0% - - 50% 95% 21% 93% 70% 94% 20% 0% 0% 
2.68 [0.39, 4.96] -0.31 [-0.53, -0.09] -0.13 [-0.31, 0.06] -0.48 [-1.26, 0.31] -0.36 [-1.14, 0.41] 0.28 [-0.21, 0.78] 1.16 [-0.33, 2.65] -0.58 [-0.83, -0.33] -0.52 [-1.07, 0.04] -13.50 [-32.50, 5.49] 
-9.20 [-45.39, 
27.00] 0.77 [0.49, 1.22] 1.14 [0.63, 2.06] 0.77 [0.38, 1.53] 
CD34+ cells 
<12 months 
2[65] 2[65] 1[20] 1[53] 0[0] 1[45] 0[0] 1[20] 1[20] 0[0] 0[0] 1[20] 0[0] 0[0] 
<0.00001 0.06 0.12 <0.00001 - <0.00001 - <0.00001 <0.00001 - - - - - 
82% - 83% - - - - - - - - - - - 
8.25 [4.78, 11.71] -1.54 [-3.18, 0.09] -0.72 [-1.63, 0.19] -2.42 [-3.13, -1.70] - 3.45 [2.50, 4.40] - -2.10 [-2.59, -1.61] -2.00 [-2.66, -1.34] - - - - - 
≥12 months 
1[45] 1[45] 0[0] 1[45] 0[0] 1[45] 0[0] 0[0] 0[0] 0[0] 0[0] 1[110] 0[0] 1[110] 
<0.00001 <0.0001 - <0.00001 - <0.00001 - - - - - 0.02 - 0.02 
- - - - - - - - - - - - - - 
6.51 [5.13, 7.89] -1.49 [-2.16, -0.82] - -15.51 [-18.91, -12.10] - 2.76 [1.92, 3.60] - - - - - 0.42 [0.20, 0.88] - 0.42 [0.20, 0.88] 
CD133+ cells 
<12 months 
3[136] 2[106] 3[136] 0[0] 1[54] 0[0] 1[42] 1[54] 1[54] 0[0] 0[0] 1[77] 2[110] 3[166] 
0.46 0.19 0.71 - 0.48 - 0.85 0.04 0.004 - - - 0.96 0.21 
78% 0% 0% - - - - - - - - - - 0% 
-1.66 [-6.11, 2.79] 0.25 [-0.13, 0.64] 0.06 [-0.27, 0.40] - 0.19 [-0.33, 0.72] - 0.06 [-0.56, 0.68] 0.48 [0.02, 0.94] 0.54 [0.17, 0.91] - - - 1.08 [0.07, 16.67] 1.31 [0.86, 1.99] 
≥12 months 
0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 2[93] 0[0] 0[0] 
- - - - - - - - - - - 0.61 - - 
- - - - - - - - - - - 0%  - 
- - - - - - - - - - - 0.63 [0.10, 3.81] - - 
ALDH+ cells 
<12 months 
1[20] 1[20] 1[30] 0[0] 0[0] 0[0] 0[0] 0[0] 1[20] 0[0] 0[0] 1[20] 0[0] 1[20] 
0.54 0.47 0.86 - - - - - 0.28 - - - - 1 
- - - - - - - -  - - - - - 
-2.00 [-8.45, 4.45] -0.32 [-1.21, 0.56] -0.07 [-0.83, 0.69] - - - - - 0.20 [-0.16, 0.56] - - - - 1.00 [0.83, 1.20] 
≥12 months 
0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 
- - - - - - - - - - - - - - 
- - - - - - - - - - - - - - 
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Mean at endpoint 
quality of life 
Change from 
baseline 
quality of life 
Mean at endpoint mortality MACEs SAEs 
- - - - - - - - - - - - - - 
BMMSCs 
<12 months 
2[94] 1[55] 1[25] 0[0] 0[0] 1[27] 1[55] 0[0] 2[89] 1[28] 0[0] 2[96] 0[0] 0[0] 
<0.00001 0.26 0.03 - - 0.67 0.76 - 0.1 0.56 - 0.73 - - 
0% - - - - - - - 56% - - 21% - - 
5.88 [4.35, 7.41] 0.32 [-0.24, 0.89] -0.94 [-1.80, -0.07] - - 0.17 [-0.63, 0.97] 0.09 [-0.48, 0.65] - -0.47 [-1.03, 0.09] -7.00 [-30.76, 16.76] - 1.48 [0.16, 14.12] - - 
≥12 months 
2[56] 0[0] 1[31] 0[0] 0[0] 1[25] 0[0] 0[0] 1[31] 1[25] 0[0] 2[65] 2[63] 1[30] 
0.59 - 0.05 - - 0.41 - - 0.14 0.4 - 0.36 0.58 0.81 
94% - - - - - - - - - - - 0% - 




4[263] 4[255] 0[0] 0[0] 0[0] 1[36] 0[0] 0[0] 0[0] 0[0] 0[0] 1[36] 0[0] 1[290] 
0.45 <0.0001 - - - 0.01 - - - - - 0.38 - 0.0002 
94% 0% - - - - - - - - - - - - 
1.52 [-2.44, 5.48] -0.52 [-0.77, -0.27] - - - 0.92 [0.22, 1.62] - - - - - 0.36 [0.04, 3.59] - 3.94 [1.91, 8.13] 
≥12 months 
3[220] 3[219] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 1[7] 0[0] 0[0] 1[271] 0[0] 0[0] 
0.95 0.0006 - - - - - - 0.03 - - 0.73 - - 
70% 9% - - - - - - - - - - - - 




3[57] 3[55] 3[55] 0[0] 3[58] 0[0] 3[57] 3[59] 0[0] 3[57] 0[0] 0[0] 0[0] 0[0] 
0.19 0.38 0.58 - 0.31 - 0.09 0.66 - 0.04 - - - - 
0% 31% 0% - 0% - 0% 0% - 0% - - - - 
2.64 [-1.33, 6.62] -0.35 [-1.14, 0.44] 0.18 [-0.46, 0.83] - 0.35 [-0.40, 1.10] - 0.54 [-0.09, 1.17] 0.09 [-0.30, 0.47] - 12.46 [0.49, 24.43] - - - - 
≥12 months 
3[56] 3[54] 3[54] 0[0] 3[52] 0[0] 3[55] 3[57] 0[0] 3[56] 0[0] 1[60] 1[60] 0[0] 
0.53 0.64 0.25 - 0.9 - 0.04 0.79 - 0.09 - 0.09 0.38 - 
0% 46% 0% - 0% - 0% 0% - 0% - - - - 
1.70 [-3.56, 6.96] 0.21 [-0.66, 1.08] 0.38 [-0.26, 1.01] - -0.04 [-0.69, 0.61] - 0.67 [0.03，1.31] -0.05 [-0.42, 0.32] - 8.63 [-1.25, 18.50] - 0.33 [0.09, 1.17] 0.67 [0.27, 1.64] - 
Ixmyelocel-T 
<12 months 
1[92] 1[92] 0[0] 0[0] 0[0] 0[0] 1[94] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 
0.27 0.67 - - - - 0.36 - - - - - - - 
- - - - - - - - - - - - - - 
1.39 [-1.08, 3.86] -0.09 [-0.50, 0.32] - - - - 0.19 [-0.22, 0.60] - - - - - - - 
≥12 months 
1[85] 1[85] 0[0] 0[0] 0[0] 0[0] 1[82] 0[0] 0[0] 0[0] 0[0] 2[168] 2[168] 1[112] 
0.66 0.68 - - - - 0.48 - - - - 0.42 0.04 0.02 
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Mean at endpoint 
quality of life 
Change from 
baseline 
quality of life 
Mean at endpoint mortality MACEs SAEs 
- - - - - - - - - - - 0% 0% - 




24[1114] 18[908] 14[501] 1[50] 4[244] 5[225] 7[413] 7[366] 12[478] 4[119] 5[235] 12[550] 5[295] 6[570] 
0.003 0.92 0.04 0.51 0.56 0.2 0.01 0.04 0.12 0.08 0.2 0.31 0.28 0.79 
87% 58% 6% - 89% 52% 83% 91% 98% 0% 94% 0% 32% 82% 
2.54 [0.89, 4.19] -0.01 [-0.23, 0.21] -0.20 [-0.39, -0.01] 0.19 [-0.38, 0.76] -0.25 [-1.09, 0.59] 0.27 [-0.14, 0.68] 0.63 [0.13, 1.14] -0.51 [-1.00, -0.01] -0.41 [-0.92, 0.10] -9.69 [-20.55, 1.17] 
-10.36 [-26.29, 
5.58] 0.68 [0.31, 1.45] 0.70 [0.36, 1.35] 1.08 [0.62, 1.90] 
≥12 months 
13[601] 8[491] 5[272] 0[0] 1[21] 2[52] 3[194] 2[109] 5[176] 3[131] 3[137] 12[879] 7[350] 6[290] 
0.22 <0.0001 0.14 - 0.48 0.4 0.08 0.0004 0.19 0.08 0.22 0.02 0.54 0.03 
89% 0% 0% - - 0% 96% 49% 94% 45% 97% 0% 11% 0% 
1.54 [-0.91, 3.99] -0.43 [-0.61, -0.25] -0.21 [-0.48, 0.07] - 0.39 [-0.70, 1.49] 0.25 [-0.32, 0.81] 1.53 [-0.18, 3.24] -0.58 [-0.91, -0.26] -0.46 [-1.15, 0.23] -13.27 [-28.21, 1.68] 
-15.45 [-40.06, 




9[370] 5[256] 6[230] 3[143] 2[60] 5[253] 2[119] 1[24] 4[103] 3[149] 2[121] 1[60] 1[29] 0[0] 
<0.0001 0.09 0.62 0.09 0.78 0.09 0.33 0.76 0.34 0.98 0.05 1 0.38 - 
62% 83% 29% 94% 0% 95% 0% - 61% 48% 0% - - - 
4.03 [2.20, 5.85] -0.57 [-1.22, 0.09] -0.09 [-0.43, 0.26] -1.44 [-3.11, 0.24] 0.08 [-0.48, 0.64] 1.13 [-0.18, 2.43] -0.18 [-0.54, 0.18] -0.10 [-0.74, 0.54] -0.24 [-0.74, 0.26] -0.13 [-8.53, 8.28] 12.29 [-0.12, 24.71] 1.00 [0.07, 15.26] 1.63 [0.55, 4.87] - 
≥12 months 
8[329] 5[258] 7[288] 2[71] 1[26] 4[180] 2[112] 1[23] 5[179] 3[138] 2[114] 7[447] 2[78] 2[140] 
0.0005 0.13 0.39 0.29 0.36 0.12 0.92 0.41 0.007 0.64 0.55 0.68 0.51 0.14 
63% 76% 0% 99% - 92% 26% - 0% 76% 55% 34% 0% 26% 




28.26] 0.89 [0.52, 1.54] 0.70 [0.25, 2.02] 0.55 [0.25, 1.23] 
both 
<12 months 
3[57] 3[55] 0[0] 0[0] 3[58] 0[0] 3[57] 3[59] 0[0] 3[57] 0[0] 1[59] 0[0] 0[0] 
0.19 0.38 - - 0.29 - 0.09 0.66 - 0.03 - 0.82 - - 
0% 31% - - 0% - 0% 0% - 0% - - - - 
2.64 [-1.33, 6.62] -0.35 [-1.14, 0.44] - - 0.33 [-0.28, 0.93] - 0.55 [-0.08, 1.18] 0.09 [-0.30, 0.47] - 12.96 [0.94, 24.98] - 0.85 [0.23, 3.22] - - 
≥12 months 
3[56] 3[54] 5[114] 0[0] 3[52] 0[0] 3[55] 3[57] 0[0] 3[56] 0[0] 2[90] 1[60] 0[0] 
0.53 0.64 0.62 - 0.9 - 0.03 0.79 - 0.07 - 0.93 0.38 - 
0% 46% 0% - 0% - 0% 0% - 0% - 0% - - 
1.70 [-3.56, 6.96] 0.21 [-0.66, 1.08] 0.11 [-0.34, 0.56] - -0.04 [-0.69, 0.61] - 0.69 [0.05, 1.33] -0.05 [-0.42, 0.32] - 9.23 [-0.61, 19.06] - 1.05 [0.35, 3.15] 0.67 [0.27, 1.64] - 
autologous <12 months 
32[1445] 23[1153] 20[741] 4[193] 4[246] 9[442] 8[496] 8[390] 16[581] 6[232] 7[356] 13[633] 6[324] 6[570] 
<0.0001 0.23 0.05 0.16 0.41 0.07 0.07 0.05 0.09 0.51 0.55 0.46 0.51 0.79 
84% 69% 13% 95% 88% 91% 86% 90% 97% 23% 93% 0% 35% 82% 
2.75 [1.39, 4.10] -0.14 [-0.36, 0.09] -0.16 [-0.33, 0.00] -1.03 [-2.47, 0.42] -0.32 [-1.10, 0.45] 0.64 [-0.05, 1.32] 0.47 [-0.04, 0.97] -0.46 [-0.91, -0.01] -0.38 [-0.83, 0.07] -1.92 [-7.58, 3.74] -4.53 [-19.23, 10.17] 0.78 [0.40, 1.51] 0.82 [0.45, 1.48] 1.08 [0.62, 1.90] 
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Mean at endpoint 
quality of life 
Change from 
baseline 
quality of life 
Mean at endpoint mortality MACEs SAEs 
≥12 months 
21[930] 13[749] 14[536] 2[71] 1[26] 6[232] 5[306] 3[132] 9[326] 6[269] 5[251] 18[1296] 9[428] 8[430] 
0.01 0.0001 0.11 0.29 0.36 0.08 0.09 <0.00001 0.11 0.14 0.46 0.06 0.23 0.006 
87% 50% 0% 99% - 87% 94% 21% 92% 70% 95% 17% 0% 0% 




12.66] 0.73 [0.53, 1.02] 0.79 [0.54, 1.16] 0.72 [0.58, 0.91] 
allogeneic 
<12 months 
3[57] 3[55] 3[55] 0[0] 3[58] 0[0] 3[57] 3[59] 0[0] 3[57] 0[0] 0[0] 0[0] 0[0] 
0.19 0.38 0.58 - 0.31 - 0.09 0.66 - 0.03 - - - - 
0% 31% 0% - 0% - 0% 0% - 0% - - - - 
2.64 [-1.33, 6.62] -0.35 [-1.14, 0.44] 0.18 [-0.46, 0.83] - 0.31 [-0.29, 0.92] - -0.55 [-1.18, 0.08] 0.09 [-0.30, 0.47] - 12.96 [0.94, 24.98] - - - - 
≥12 months 
3[57] 3[54] 3[54] 0[0] 3[52] 0[0] 3[55] 3[57] 0[0] 3[56] 0[0] 1[60] 1[60] 0[0] 
0.53 0.64 0.25 - 0.9 - 0.03 0.79 - 0.07 - 0.09 0.38 - 
0% 46% 0% - 0% - 0% 0% - 0% - - - - 
1.70 [-3.56, 6.96] 0.21 [-0.66, 1.08] 0.38 [-0.26, 1.01] - -0.04 [-0.69, 0.61] - 0.69 [0.05, 1.33] -0.05 [-0.42, 0.32] - 9.23 [-0.61, 19.06] - 0.33 [0.09, 1.17] 0.67 [0.27, 1.64] - 
revascularization 
<12 months 
11[345] 7[192] 7[219] 0[0] 1[54] 1[57] 3[129] 2[71] 4[138] 0[0] 0[0] 7[249] 2[91] 3[157] 
0.06 0.38 0.13 - 0.48 0.11 0.05 0.53 0.18 - - 0.86 0.32 0.34 
89% 76% 31% - - - 70% 98% 94% - - 0% 0% 76% 
3.39 [-0.19, 6.97] -0.29 [-0.94, 0.36] -0.27 [-0.61, 0.08] - 0.19 [-0.34, 0.73] 0.43 [-0.10, 0.96] 0.67 [-0.01, 1.34] -0.81 [-3.34, 1.72] -0.60 [-1.49, 0.28] - - 1.14 [0.28, 4.73] 2.69 [0.38, 19.05] 0.37 [0.05, 2.88] 
≥12 months 
3[89] 1[50] 1[50] 0[0] 0[0] 0[0] 1[30] 0[0] 1[30] 0[0] 0[0] 5[213] 3[123] 2[89] 
0.18 0.03 0.18 - - - <0.0001 - 0.0001 - - 0.47 0.38 0.66 
92% - - - - - - - - - - 0% 0% 0% 
5.83 [-2.66, 14.33] -0.63 [-1.20, -0.06] -0.38 [-0.94, 0.18] - - - 1.76 [0.90, 2.62] - -0.73 [-1.10, -0.36] - - 0.70 [0.27, 1.82] 1.55 [0.66, 3.65] 1.18 [0.56, 2.49] 
no revascularization 
<12 months 
26[1203] 21[897] 16[581] 4[193] 8[308] 9[421] 9[460] 9[375] 12[443] 10[325] 7[356] 9[482] 4[233] 4[432] 
<0.0001 0.13 0.32 0.16 0.86 0.06 0.1 0.05 0.24 0.98 0.55 0.25 0.32 0.62 
79% 63% 0% 95% 77% 91% 81% 65% 97% 24% 93% 0% 42% 91% 
2.70 [1.42, 3.97] -0.17 [-0.38, 0.05] -0.09 [-0.26, 0.09] -1.03 [-2.47, 0.42] -0.05 [-0.61, 0.51] 0.70 [-0.02, 1.41] 0.41 [-0.07, 0.89] -0.25 [-0.51, 0.00] -0.31 [-0.83, 0.21] 0.05 [-5.21, 5.32] -4.53 [-19.23, 10.17] 0.68 [0.35, 1.31] 0.73 [0.40, 1.35] 1.23 [0.50, 3.02] 
≥12 months 
21[897] 15[753] 14[509] 2[71] 6[149] 6[232] 7[331] 6[189] 9[325] 9[325] 5[251] 16[1173] 7[365] 7[361] 
0.05 0.003 0.39 0.29 0.83 0.08 0.09 0.02 0.19 0.56 0.46 0.04 0.04 0.005 
84% 53% 0% 99% 99% 87%% 90% 49% 93% 61% 95% 29% 0% 0% 
1.74 [-0.03, 3.51] -0.35 [-0.58, -0.12] 0.08 [-0.26, 0.10] -7.90 [-22.63, 6.83] -0.04 [-0.38, 0.31] 0.75 [-0.08, 1.57] 0.73 [-0.11, 1.57] -0.34 [-0.63, -0.05] -0.38 [-0.96, 0.19] -2.28 [-9.87, 5.31] 
-7.55 [-27.76, 
12.66] 0.68 [0.48, 0.98] 0.67 [0.46, 0.99] 0.72 [0.58, 0.91] 
<1 Mio <12 months 
2[45] 2[45] 2[25] 0[0] 0[0] 0[0] 0[0] 0[0] 0[1] 0[0] 0[0] 2[84] 0[0] 1[61] 
0.35 0.22 0.18 - - - - - - - - 0.72 - 0.02 
0% 25% 0% - - - - - - - - 0% - - 
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Mean at endpoint 
quality of life 
Change from 
baseline 
quality of life 
Mean at endpoint mortality MACEs SAEs 
1.68 [-1.84, 5.20] -0.45 [-1.18, 0.27] -0.62 [-1.52, 0.28] - - - - - - - - 0.71 [0.11, 4.55] - 0.09 [0.01, 0.72] 
≥12 months 
0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 0[0] 
- - - - - - - - - - - - - - 
- - - - - - - - - - - - - - 
- - - - - - - - - - - - - - 
1-10 Mio 
<12 months 
18[878] 13[687] 13[587] 2[80] 4[246] 6[319] 7[441] 6[346] 12[47] 5[204] 6[301] 7[365] 4[284] 4[219] 
0.02 0.48 0.91 0.3 0.41 0.84 0.07 0.18 0.57 0.54 0.39 0.15 0.29 0.96 
79% 27% 0% 0% 88% 37% 87% 83% 98% 35% 93% 0% 0% 0% 
2.31 [0.60, 4.01] 0.07 [-0.12, 0.25] -0.06 [-0.24, 0.11] 0.23 [-0.21, 0.68] -0.32 [-1.10, 0.45] 0.03 [-0.26, 0.33] 0.52 [-0.05, 1.10] -0.26 [-0.63, 0.11] -0.22 [-0.75, 0.31] -2.15 [-9.03, 4.73] -6.71 [-22.12, 8.70] 0.71 [0.32, 1.57] 0.79 [0.52, 1.21] 1.00 [0.85, 1.18] 
≥12 months 
11[513] 9[485] 10[460] 1[26] 1[26] 4[162] 5[306] 3[132] 7[280] 5[244] 5[251] 13[805] 7[346] 4[230] 
0.01 0.01 0.21 0.23 0.36 0.26 0.09 <0.00001 0.05 0.19 0.53 0.08 0.07 0.02 
84% 10% 0% - - 50% 94% 21% 94% 75% 95% 20% 17% 0% 
3.31 [0.78, 5.85] -0.24 [-0.44, -0.05] -0.12 [-0.31, 0.07] -0.48 [-1.26, 0.31] -0.36 [-1.14, 0.41] 0.28 [-0.21, 0.78] 0.95 [-0.14, 2.03] -0.58 [-0.83, -0.33] -0.54 [-1.10, 0.01] -9.07 [-22.50, 4.35] 
-6.76 [-27.95, 
14.44] 0.76 [0.55, 1.04] 0.71 [0.49, 1.03] 0.74 [0.57, 0.96] 
10-100 Mio 
<12 months 
9[279] 6[189] 6[137] 1[60] 2[44] 1[60] 3[97] 3[64] 3[108] 2[42] 1[55] 4[153] 1[14] 0[0] 
<0.0001 0.38 0.06 <0.00001 0.38 <0.00001 0.16 0.44 0.006 0.01 0.21 0.6 0.17 - 
72% 87% 21% - 0% - 0% 96% 85% 0% - 0% - - 
4.46 [2.11, 6.81] -0.42 [-1.34, 0.51] -0.24 [-0.61, 0.13] -2.20 [-2.85, -1.55] 0.29 [-0.35, 0.92] 2.27 [1.61, 2.93] 0.31 [-0.13, 0.74] -0.62 [-2.18, 0.94] -0.96 [-2.02, 0.10] 16.19 [3.58, 28.80] 7.92 [-4.40, 20.24] 0.72 [0.11, 4.83] 7.00 [0.43, 114.70] - 
≥12 months 
6[153] 2[40] 5[129] 0[0] 2[40] 0[0] 2[41] 2[42] 2[29] 2[41] 0[0] 6[170] 5[155] 2[60] 
0.34 0.12 0.65 - 0.7 - 0.02 0.97 0.94 0.03 - 0.34 0.73 1 
4% 22% 30% - 43% - 0% 0% 0% 0% - 0% 0% 0% 
1.07 [-1.12, 3.26] 0.61 [-0.16, 1.39] 0.11 [-0.36, 0.58] - -0.18 [-1.09, 0.73] - 0.79 [0.11, 1.48] -0.01 [-0.40, 0.38] 0.04 [-0.90, 0.97] 12.04 [1.38, 22.69] - 0.68 [0.31, 1.49] 0.90 [0.50, 1.62] 1.00 [0.34, 2.91] 
>100 Mio 
<12 months 
7[370] 6[335] 2[61] 1[53] 1[28] 3[108] 2[64] 1[29] 1[34] 3[92] 0[0] 0[0] 0[0] 1[290] 
0.05 0.02 0.12 <0.00001 0.18 0.1 0.14 1 0.01 0.94 - - - 0.0002 
92% 54% 48% - - 93% 0% - - 0% - - - - 
2.89 [-0.04, 5.82] -0.42 [-0.75, -0.08] -0.58 [-1.31, 0.14] -2.41 [-3.13, -1.69] 0.51 [-0.24, 1.27] 1.49 [-0.27, 3.26] 0.38 [-0.12, 0.88] 0.00 [-0.46, 0.46] -0.80 [-1.41, -0.19] 0.41 [-9.90, 10.73] - - - 3.94 [1.91, 8.13] 
≥12 months 
7[349] 5[291] 2[59] 1[45] 1[24] 2[70] 1[27] 1[29] 1[34] 2[53] 0[0] 6[513] 3[93] 2[140] 
0.42 0.0003 0.2 <0.00001 0.45 0.2 0.23 0.6 0.11 0.87 - <0.05 0.7 0.35 
93% 57% 33% - - 94% - - - 0% - 12% 0% 52% 
1.43 [-2.04, 4.91] -0.69 [-1.07, -0.31] -0.42 [-1.05, 0.22] -15.51[-18.91, -12.10] 0.31 [-0.49, 1.12] 1.55 [-0.81, 3.91] 0.47 [-0.30, 1.23] -0.13 [-0.61, 0.35] -0.80 [-1.79, 0.19] 
-0.85 [-10.76, 
9.05] - 0.65 [0.42, 0.99] 0.85 [0.37, 1.94] 0.63 [0.24, 1.66] 





A crossover clinical study is a prospective study where patients are assigned to a 
crossed sequence of treatments and hence is considered a valid and important type of 
trial design157. Each patient serves as their own control which can minimize confounding 
covariates. However, its noted disadvantage involves confounding treatment effects 
caused by carry-over effects. Stem cells injected after transplantation that successfully 
engraft in the target areas have been proven to survive for long durations and function in 
their specific “intended” ways. Therefore, the carry-over effects of these stem cells can 
last as long as they exist. The methods of delivering stem cells into the heart are 
commonly invasive. This means a high-quality crossover trial designed as a double 
blinded RCT is nearly impossible, because in such trials each patient has to receive 
thoracotomy and invasive cell transplantation twice, or else blinding is easily violated. 
During retrieval and inclusion, three crossover trials were excluded. One was a single-
arm crossover trial, and one was still ongoing (or completed but no published yet). 
Another cross-over trial was reported, and in that trial158 the ischemic tolerant 
mesenchymal stem cells (itMSC) were given to patients in the treatment group, and 
crossover was performed only after three months. It was therefore excluded due to too 
short follow-up and likely carry-over effects. 
Among 42 enrolled RCTs for meta-analysis, 13 trials did not perform well in blinding, 
and two did not report details. Most of them were open-label trials using autologous stem 
cells that originated from bone marrow or skeletal muscles. In cases of invasive stem cell 
harvest, but with a possible future sham injection, patients were less willing to participate 
in randomized control trials. In CAuSMIC125 and SEISMIC126 trials, muscle biopsies were 
only performed in patients in the treatment group, and control patients would only receive 
medical therapy. The same open-label design was also seen in autologous BM-derived 
stem cell transplantation. For example, in Patel 2005142 investigators performed off-pump 
coronary artery bypass grafting in patients from treatment and control groups, but the 
patients in the treatment group would tolerate bone marrow aspiration. In Zhao 201568, 
only patients in the cell therapy group were treated with allogeneic UCMSCs through 
catheter-based intracoronary delivery, but patients in the control group only received 
conventional medical treatments. In these 15 trials (either did not perform well in blinding 
or did not report in details), risk of performance bias existed, since investigators would 
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devote more attention to them, causing the difference in medical care levels. Besides that, 
the possibility of a conflict of interest leading to false-positive results was highly possible. 
Investigators who were aware of group assignments tended to modulate medical 
treatments to get positive outcomes. In unblinded trials, if blocked randomization was 
used, especially with a fixed size, the bias would happen due to a predictable future. 
Therefore, in sensitivity analyses, trials with high risks of performance bias were isolated 
to reduce the heterogeneity and verify the robustness of the results. 
Attrition bias happens in a situation of incomplete outcome data. Less than 5% of 
loss during follow-up could be accepted, but more than 20% attrition can severely 
threaten validity159. In the MiHeart trial137, 45 patients out of a total of 160 were lost during 
follow-up, causing a high risk of attrition bias. Twenty-one patients were lost in the 
treatment group (n=82) and 24 lost in the control group. The details were not discussed 
in that paper, but common reasons for abandonment in heart failure might be a severe 
illness, or dissatisfaction with poor efficacy. In their primary outcome as LVEF change 
from baseline, no significant difference was shown between the two groups. If we assume 
the worst-case scenario, which is that lost patients in the treatment group all had 
increased LVEF, and all lost patients in the control group had decreased LVEF or vice 
versa, the outcomes could changed from statistically insignificant to significant or vice 
versa. 
Patients who felt dissatisfied with their treatments during clinical trials would declare 
withdrawal of consent in order to obtain better medical services, which would cause an 
excessive lack of negative results. To avoid this situation, investigators designed a single 
crossover from controls to the experimental group. For example, in FOCUS-HF63 and 
FOCUS-Br145 trials, patients who were randomized to control groups would be given the 
experimental treatments after a certain period of follow-up. Transendocardial injections 
were applied in these studies, which is practicable to be performed in trial-crossed control 
patients twice, thereby keeping blindness and avoid post-operative trauma at the same 
time. 
Another type of incomplete data happened in trial Ang 2008127 and Steinhoff 2017150 
when patients were still reachable but rejected participation in imaging assessment of 
cardiac functions. In Ang 2008127, 60 patients were randomized and treated, but at the 
follow-ups, only 33 patients participated in MRI assessments. Thus, the validity of primary 
outcomes was threatened by their rejection. 
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Three trials did not report all the outcomes mentioned in their methods. In these trials, 
outcomes with insignificant results were mentioned, but the details of the data were 
missing, which caused a risk of reporting bias in meta-analysis.  
Clinical outcomes and overall effects 
In stem cell trials, cardiac functional improvement generally manifests as an increase 
of LVEF, which is mostly set as the primary outcome for evaluating the effectiveness and 
efficacy of stem cells in cardiac repair. The increase in LVEF should not be attributed to 
a single beneficial function from stem cells but be viewed as a comprehensive result due 
to different effects, including anti-apoptosis, immunomodulation, cardiomyogenesis, and 
angiogenesis. Therefore, it is considered as one of the most suitable clinical indicators of 
whether stem cells could truly function well in cardiac repair. For example, myoblasts 
were once thought to be quite promising in heart regeneration for their myogenic property 
and tolerance to ischemic environments but failed to show any improvement in LVEF in 
RCTs. Conversely, BM-derived cells that mainly reported with specific paracrine effects 
demonstrated an increase of over 2%.  
In the overall effect of stem cells in LVEF, a mean 3.2% increase over the control 
group was obtained in this meta-analysis; however, responders to stem cell therapies in 
clinical tirals are commonly defined by an increase over 5%160,161. Data from a pilot 
study160 showed that 48% of patients responding well to heart failure therapy had LVEF 
increases of ≥ 5% and 57% had 6MWD > 50 meters, and a strong association between 
the clinical relevant increase in LVEF and the improvement in 6MW-test was also 
revealed. Moreover, responders also had a better outcome with respect to all-cause 
mortality and hospitalization. Therefore, the increase in LVEF at 5% was set as a predictor 
in the prognosis of stem cell therapy for heart failure162.  
Meta-analyses of bone marrow-derived mesenchymal stem cells in heart repair 
reported improvements of LVEF in all animal models. Nevertheless, different efficacies of 
BMMSCs exist among different animal models79. In small animals, BMMSCs were 
demonstrated to increase LVEF by ≈12% over controls. In large animal models, LVEF 
improvement kept at ≈12% in chronic ischemic cardiomyopathy but dropped to ≈7% in 
the models of acute myocardial infarction. A similar discrepancy in clinical efficacy 
between small and large animals was also seen with cardiac stem cells163. Cardiac stem 
cells were associated with an 11.51% increase of LVEF in small animal models, but a 
5.22% increase in large ones. The pooled effect of all stem cell types on LVEF was ≈7% 
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in preclinical trials71,83; however, it was proven to be around 2-4% in clinical trials164–167. 
For patients with heart failure, a 2.06% LVEF increase was found after less than 1 year 
and only 1.26% over 1 year114, which is consistent with the results from our meta-analysis 
where we found an overall effect of a 2.88% increase in LVEF with stem cells in less than 
12 months and 2.33% at the 12-month or longer follow-up. The disparity between a 5-13% 
increase in animals and nearly 2-4% in patients represents a dissatisfying transition from 
bench to bedside in stem cell therapy for heart failure. Tentative explanations for different 
aspects will be described below. 
Patients with stable heart failure included in clinical trials were several months after 
MI, or had chronic dilated cardiomyopathy with diverse etiologies. Successive loss of 
cardiomyocytes and the progression of ventricular dilation in heart failure, as mentioned 
in the background, is different from an active inflammatory reaction to massive cell death 
after MI. Animal models that were studied for cardiac repair were commonly conducted 
in two ways, with coronary artery permanent ligation and ischemia-reperfusion cycles, 
which could not be used to simulate the microenvironments of chronic decompensating 
hearts. 
The efficacy gap between animal experiments and clinical trials could also be 
attributed to inequivalent injected cell doses. The cell doses injected into small animals 
like mice and rats were mostly applied in a range of 0.1-10 million, while in large animals 
with similar heart size as human beings, cell doses were used from 10 to >100 million, 
which was relatively lower than those used in small animals79,163. If we assume the same 
percentage of cardiomyocytes loss after MI, and the same survival rate of stem cells after 
transplantation, in addition to a similar heart-to-body mass ratio in mammals in mice and 
swine168, the equivalent dose of 0.1 million stem cells into mice  (≈20g) would be over 1 
trillion into swine (≈200kg). At least 300 - 400 million stem cells would be needed if the 
investigators wanted to successfully repeat the positive results in adult patients (60-80kg). 
Obviously, stem cell injection at these doses was hard to be performed in clinics.  
Moreover, assessments of cardiac functions in animal experiments were usually 
performed less than 12 weeks after injection, while the measuring time in clinical trials 
was mostly at 6 months. However, improvement in LVEF due to stem cells began to fade 
as early as 9 weeks after injection83. In clinical trials, patients receiving bone marrow cells 




Influence of cell cultivation 
An extra explanation for applying random effect models in meta-analysis is needed 
here: Since clinical trials differ reasonably in regard to treatment regimens, clinical 
heterogeneity caused by patient selection, trial methodologies, or duration of follow-up, 
etc., and they also differ in statistical heterogeneity. Simple, direct conclusions drawn 
from the overall results would be too imprecise and less convincing for validating the 
effectiveness of stem cells in cardiac repair170. In case of high heterogeneities, random 
effect analyses were applied, and subgroup analyses in terms of cell cultivation and cell 
origins, etc. were executed in order to better understand the clinical relevance from the 
results. 
In 2000, the first stem cells used in clinical trials for HF treatment were myoblasts171. 
Although the application of cultured stem cells began earlier than primary cells, primary 
cells were preferred in clinical use for their convenient isolation and short preparation time. 
But over years of development, cultured cells gradually became more adopted, due to 
higher injected cell density after cell cultivation. However, the maintenance of stem cell 
quality during passaging became a severe challenge172. CD34 biomarkers lost during 
subsequent cultivation173,174. Properties of stem cells were modulated by medium 
components like basal medium and medium serum175,176. In practice, FBS was reported 
to cause cessation of cell cycling, suppression of proliferation-related and cell cycle-
related genes, and other types of genes such as growth factors and metabolism-related 
genes. Combined with different growth factors, FBS could increase MSC proliferation but 
also negatively affect their immune-phenotypes177. Human-derived serum products like 
pooled human platelet lysate and autologous or allogeneic human serum seemed to be 
the best candidates for medium serum but were identified to compromise their immuno-
suppressive properties of MSCs, and were suspicious of changing gene expression by 
undefined proteins178–180. Thus, the alterations of large amounts of gene expressions in 
in-vitro expanded stem cells compared to purified uncultured stromal stem cells181 and 
remarkably impaired stemness and pluripotency indicate that cultured cells might not be 
ideal for cell therapies182. 
Influence of cell origins 
No increase in LVEF was discovered with myoblasts. No other improvement, except 
an increase in NYHA functional status at long-term follow-up, was achieved. As pointed 
out in the Introduction, the effectiveness of myoblasts in heart repair was expected 
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through transdifferentiating into cardiomyocyte-like cells; however, retention and survival 
rates were measured as quite low. To date, 17 clinical studies are on record, 16 have 
been published and only one that began in 2007 is still ongoing or already suspended. 5 
out of 16 studies were RCTs that began between 2002 and 2007, and the latest myoblast 
study was initiated in 2010. It is not surprising that the negative results from the completed 
RCTs and the evidence of inducing ventricular arrhythmias impeded further clinical trials 
of myoblasts. In contrast, positive results from bone marrow-derived cells raised more 
interest in widespread applications. 
Perinatal stem cells increased LVEF after short- and long-term follow-ups; the mean 
effect sizes in LVEF increase were both over the 5% line. As described in the introduction, 
perinatal stem cells (UCMSCs in Figure 1) are more advantageous in immune evasion, 
paracrine secretion, and survivability under unfavorable conditions. Therefore, the 
superiority of perinatal stem cells for heart recovery from ischemic injury is suggested in 
this meta-analysis, and further experiments are needed. 
Ongoing trials 
Although the Egger’s test has proven no publication bias in the overall primary 
outcomes at both short- and long-term follow-ups, the effectiveness and efficacy of some 
specific cell types should be carefully affirmed due to limited published trials. For instance, 
umbilical cord mesenchymal stem cells were shown to cause the highest increase in 
LVEF and strongly induce LV remodeling reversion; however, only two trials were 
included in this meta-analysis. Hence, the results of ongoing UCMSC trials are highly 
anticipated so that more data will be pooled and analyzed to see whether they are 
consistent with published ones. Furthermore, two trials of allogeneic ATMSCs are 
awaiting completion. Among ongoing trials of BM-derived cells, 4 are studying BMMSCs, 
2 are studying BM-derived mesenchymal precursor cells, and 1 is studying CD34+ cells.  
Limitation 
This analysis is a literature-based meta-analysis with 42 included RCTs. Efforts have 
been made to obtain missing but necessary data. For these missing data, which were still 
unavailable after data requests, a calculation using formulas, based on the Cochrane 
Guide and other publications, was employed to maximize dataset. Meanwhile, we are 
aware of the associated disadvantage, whereas the calculated data could impact the 
robustness of the results. 
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Insufficient data represents very weak evidence to be used for drawing any 
conclusions about specific cells. As discussed in the section of ongoing trials, more RCTs 
are expected to be added in the future. 
Conclusion 
Despite decades of research in stem cell therapy for heart failure treatment, clincal 
science is still at any early stage of finding the ideal cell type that provides optimal cardiac 
functional improvements and reduced mortality. Benefits from stem cell therapy should 
be clinically significant; the benefits should also maintain stable after a long-term follow-
up. From this meta-analysis of 42 RCTs, we learned that stem cells could reduce all-
cause mortality in HF patients, but their improvement in LVEF showed no clinical 
significance. Perinatal stem cells might have the potential to be efficient in HF treatment, 
but definitive confirmation still requires more RCTs. Inappropriate trial design and 
execution causing high risks of selection and performance biases could produce false-
positive results that significantly impact the robustness of the results and should be 



























Part II. Application of human sera in the cultivation of cord blood-





In the introduction of Part I, we described the relevant properties of MSCs in clinical 
trials that focosed on cardiac repair. In recent years, the application of MSCs for cardiac 
repair has been questioned as a result of unsatisfactory pooled clinical outcomes183. 
Their cardiomyogenic capacity has been observed in vitro but no in vivo data has 
supported this claim 23,24, while their angiogenic properties have been confirmed by 
many studies184,185. MSCs transdifferentiate into endothelial cells and also secrete 
beneficial growth factors and microRNAs. It is clear that MSCs are regenerative cells 
and are also worthy of clinical application; however, evidence as differentiation into 
cardiomyocytes is missing. In contrast, their anti-apoptotic and immunomodulative 
capabilities have been well studied. 
Cell rescue from ischemia-reperfusion injury 
Under oxidative stress, especially severe ischemia-reperfusion (I/R) injury, reactive 
oxygen species formation (ROS) and calcium overload are the two main pathological 
consequences that lead to mitochondrial damage and ultimately to cell death186. 
Autophagy is an intrinsic self-rescuing mechanism in cells that is activated by the same 
stimuli and helps cells survive in adverse conditions. Exosomes from MSCs were reported 
to prevent cardiomyocyte deaths by inducing autophagy potentially via the activation of 
AMPK and Akt pathways187. Similarly, co-culturing with MSCs can restore mitochondrial 
respiratory function and ATP production in hibernating myocardium188. The proliferator-
activated receptor gamma coactivator 1-alpha-driven mitochondrial biogenesis was also 
observed to increase after co-cultivation. Since the mitochondrial transfer was discovered 
during co-cultivation, another explanation for the mechanism of their anti-apoptotic 
function was introduced. There are several schematic patterns of mitochondrial transfer, 
with tunneling nanotubes being the most well studied in the cardiovascular field189. The 
transfer was demonstrated via stained donor MSCs mitochondria that were seen inside 
recipient myoblasts with TNT-like structures connecting each other. TNT formation 
inhibitor restrained the anti-apoptotic potential in the co-culture system190. Animal 
cardiomyocytes were later reported to receive mitochondria from MSCs of different origins, 
including BMMSCs, ADMSCs, dental pulp MSCs and Wharton’s jelly MSCs (WJMSCs), 
and WJMSCs performed best in reducing mtROS in cardiomyocytes191.   
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Immunomodulation to prevent overactive inflammation after ischemia-reperfusion 
injury 
The rupture of cell membrane releases pro-inflammatory substances and leads to an 
unbalanced inflammatory reaction that plays a critical role in sustainable cell loss and 
tissue damage after I/R injury186. Mesenchymal stem cells regulate immune cells in regard 
to multiple aspects. They not only promote macrophage and dendritic cell polarization 
toward an anti-inflammatory phenotype but also suppress both T and NK cell 
proliferation192. Additionally, they are known to promote the induction of regulatory B-cells, 
which leads to immunological tolerance. Counterintuitively, apoptotic MSCs were 
reported to be even more effective than living MSCs in tissue protection against 
inflammation, oxidative stress, and apoptosis193,194. This “dying stem cell hypothesis” 
could be traced back to 2005195 in which apoptotic MSCs were proposed to suppress 
immunoactivity in local regions. Further studies suggested that this might be due to the 
release of intracellular membrane particles196. MSCs were damaged in 4°C cold water, 
and the separated released membrane particles were found to negatively regulate the 
activity of pro-inflammatory monocytes. Even more, when MSCs were stimulated by IFN-
γ that is only secreted by both activated T and NK cells, the isolated membrane particles 
could additionally cause an increase in the percentage of anti-inflammatory monocytes. 
In a publication from the same research group, heat-inactivated MSCs, which were not 
capable of secreting extracellular particles or actively participating in cross-talk with 
immune cells, were still immunomodulatory, probably through the cognition of membrane 
biomarkers by immune cells197. 
MSCs transplantation for post-operative complications 
Post-operative complications after cardiac surgery, such as stroke, renal failure, and 
prolonged intubation, are recognized to be the major contributors to operative death198. 
The invention of the cardiopulmonary bypass (CPB) created the opportunity for the 
development of cardiac surgeries. However, in many retrospective studies the prolonged 
CPB running time and combined heart procedures, such as CABG combined with valvular 
surgeries, have been shown to be independent factors of early stroke, acute renal failure, 
delayed extubation, and post-operative low cardiac output syndrome (LCOS)199–203. 
Hemolysis, hemodilution, and unstable hemodynamics during CPB would cause local 
inflammation, hypoxemia, and cell loss in multiple organs. Thus, considering MSCs 
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properties of anti-apoptosis and immunomodulation, it is reasonable to investigate 
whether they are effective or efficient in preventing incidence of severe post-operative 
complications after a long, complicated cardiac surgery.   
In stroke patients, MSCs were demonstrated to attenuate those pathophysiological 
processes, showing that the lesion volume was reduced by nearly 20%204. Despite 
insignificant outcomes from several animal experiments to restore kidney function205,206, 
preventative post-operative applications of MSCs are still of great interest (undergoing 
clinical trials: registered trials of NCT04194671 & NCT03552848 in clinicaltrials.gov). 
Similarly, MSCs were proven to attenuate pulmonary vascular permeability and 
ameliorate acute lung injury in animal models207,208, yet no specific data from clinical trials 
in this area has been published.  
Cardiac injury after long-term CPB often manifests as cardiac stunning, post-
operative low cardiac output syndrome, and even cardiogenic shock. An increasing 
release of cardiac biomarkers was detected after long-term CPB209. Mitochondrial 
dysfunction, microvascular endothelial dysfunction, and unrestricted inflammation are 
thought to be the main pathological changes in I/R injury210. The application of MSCs 
could lower the cellular stress response to I/R injury. In a swine model of CABG surgery, 
mitochondrial morphology and function were improved by MSC transplantation211. MSC 
transplantation, combined with hyperbaric oxygenation, was demonstrated to cause 
significant recovery in tissue oxygenation two weeks after ischemia simulation212. The 
oxygenation of cardiac tissue was assessed by a new technique termed electron 
paramagnetic resonance (EPR), which has been utilized in several studies to evaluate 
mitochondrial function preservation via different therapies after ischemic cardiac injury213. 
Although MSC-induced anti-apoptotic and anti-inflammatory effects on injured 
cardiomyocytes have been explored abundantly in animal models, MSC clinical trials for 
post-operative cardiac complications are still scarce. No record of any registered clinical 
trials of stem cells for post-operative cardiac complications was shown in clinicaltrials.gov, 
and there are also no relevant data from trials studying other cardiac diseases. Most 
relevant trials were registered for ischemic heart disease and cardiomyopathy, and the 
outcomes are mainly mortality, SAEs, LVEF, LVEDV, NYHA, and others instead of 
angiogenesis or immune-relevant clinical indicators. 
Arrhythmia is the most common post-operative complication indicating cardiac injury, 
a prognosis with a higher risk in morbidity, increased length of hospital stay, and an 
increase in economic costs214. Unstable hemodynamics could also aggravate other 
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comorbidities; abnormal perfusion aggravates post-operative cerebral dysfunction, renal 
insufficiency, and other complications. It is still controversial whether MSCs could be 
applied to treat arrhythmias. Animal experiment studies showed MSCs to be pro-
arrhythmic, but others also found that they could ameliorate the inducibility of ventricular 
arrhythmias by enhancing electrical viability214–216. Results from any relevant clinical trials 
are not yet available either. 
Application of perinatal stem cells 
Perinatal mesenchymal stem cells seem to be promising for prevention of post-
operative complications after cardiac surgery. Compared to other sources of MSCs, as 
discussed in the introduction of Part I, perinatal stem cells are more proliferative, less 
senescent, and have higher immunomodulative properties. Age-related damage such as 
DNA-damage and telomere dysfunction are not present in perinatal MSCs217–219. In 
contrast to aging MSCs, for example, aging autologous MSCs from old patients, MSCs 
from younger donors are more resistant to ROS and can preserve more therapeutic 
potency under unfavorable conditions during transplantation220. Therefore, perinatal 
MSCs could be a good alternative to cells that have been mostly applied in clinical trials, 
such as autologous BMMSCs.  
Compared to other perinatal stem cells, such as WJMSCs and UCMSCs, CBMSCs 
are more easily isolated in the lab. Many public and private cord blood banks exist 
worldwide, which is a huge advantage over the other cell types. Nevertheless, the 
disadvantage is also clear in which a low yield of primary cells has been seen. Only a 
very limited amount of cord blood can be obtained at the time of birth, and the primary 
plastic adherent cell yield is often not satisfactory. Thus, long-term in vitro expansion is 
needed to reach the minimum injection dose. 
Issues during preparation for transplantation 
The choice of media serum becomes an issue and needs much deliberation. In 
Figure 8, we summarized the application of different medium sera from 42 clinical trials 
that used the cultured stem cells for heart failure treatment. Thirty trials used FBS in their 
expansion medium. Human serum was only applied in a total of eight clinical trials, of 
which five were autologous heart failure serum, two were allogeneic platelet lysate, and 
another one was allogeneic donated serum. The application of FBS introduces 
xenogeneic substances to human stem cells during in vitro cultivation and results in  
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inferior proliferation profiles and a wide range of gene down-regulation175. Autologous HF 
serum was also found to impact the clonality and proliferation profiles of CB-MSCs221. 
Therefore in Part II, different proliferation profiles among FBS, healthy control serum, and 
heart failure serum will be compared.  
On the other side, a critical factor for successful stem cell engraftment is cell survival 
in the target area. We noticed that the procedure of cell transplantation, for instance, 
syringe production, transportation, and final injection, would bring massive stress, 
especially oxidative stress to the transplanted cells. Thus, in this study we investigated 
the responses of CB-MSCs in different medium sera to the programmed ischemia-
reperfusion injury simulating the conditions during cell transplantation. Hypoxic 
preconditioning was also given to those cells to test if this additional method could be 
used to increase their survivability. 
 
Figure 8. Applications of different medium sera during in vitro expansion. 




The in vitro research on CB-MSCs was based on the following hypotheses: 
1. The proliferation capacity of CB-MSCs would be more preserved when they are 
cultured with human serum.  
2. The resistance of CB-MSCs against ischemia-reperfusion injury, which mimics the 
situation during clinical transplantation, is better under human serum cultivation. 





In accordance with the Declaration of Helsinki, this study was approved by the 
ethics committee of Charité-University Medicine Berlin. Potential patient donors were 
those who had been confirmed heart failure with reduced ejection fraction (HFrEF) and 
had received maximal medical treatments during hospitalization. Those who had 
reduced LVEF (<40%) confirmed by echocardiography, with class III or IV heart failure 
functional status (NYHA III or IV), were further enrolled. Meanwhile, patients who had 
malignant tumors, infectious disease, and diabetes and were excluded. In parallel, older 
healthy volunteers without a history of myocardial infarction (MI) or any sign of 
cardiovascular diseases (CVDs) were also enrolled and assigned to the control serum 
group. Each donor was informed of the scientific application of their serum and every 
participant signed the informed consent form. 
Serum extraction 
Blood was drawn using a BD Vacutainer Safety-Lok blood collection set. Whole blood 
samples were left undisturbed at room temperature for 30 minutes, and then centrifuged 
at 3500 g for 15 mins at 4°C to remove the clotting, and all remaining cellular particles. 
Serum supernatants were then sterilely filtered, aliquoted, flash-frozen in liquid nitrogen 
and then stored at -80°C for later use. Samples with hemolytic serum present were 
excluded. In order to minimize systematic errors, serum concentrations were normalized 
to the lowest concentration within our samples by dilution with DPBS containing Ca2+ and 
Mg2+. The total protein concentration of each sample was quantified in all human serums 
using the Pierce BCA Protein Assay Kit. Details of experimental materials were listed in 
Table 6. 
In vitro cultivation of human CB-MSCs 
Human cord blood mesenchymal stromal cells were made available by courtesy of 
Dr. K. Bieback, who isolated them from umbilical cord blood, and expanded them based 
on an optimized, previously published protocol222. Prior to experimentation, CB-MSCs 
were expanded in 1g/L glucose DMEM with 10% FBS under antibiotic protection with 1% 
Streptomycin/Penicillin. Cells were seeded at 800-1,000 cells/cm² in T175 flasks, and 
cultured under 21% O2, 5% CO2, and at 37°C. Partial media changes were performed 
every 3 days. All cells cultured were screened for the presence of mycoplasma enzymes 
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on a regular basis. All experiments were performed on cells between passages 4 and 6. 
The phenotypes of the used CB-MSCs, as well as their ability to differentiate into 
nonhematopoietic cell types, were repeatedly confirmed in previous experiments by our 
group221. 
In vitro models for acute stress on CB-MSCs: acute Stress (AcS) 
For a model of acute stress, we chose an in vitro model of “ischemia-reperfusion 
injury”, where cells are deprived of glucose, serum, and oxygen (0.2% O2) for 4 hours, 
and then transferred back into normal culture conditions. All oxygen deprivation studies 
were performed in a hypoxic chamber. Cells were first seeded at 8-10×103/cm² and 
cultivated with human serum and 1g/L glucose for 24 hours at normal cultivation. Then, 
cells were exposed to hypoxia (0.2% O2), as well as serum and glucose deprivation for 4 
hours, followed by 4 hours of modeled reperfusion under normal cultivation settings. To 
assess their recovery, another 5 days of cultivation under the respective medium at a 
normal condition was continued after programmed acute stress. Hypoxia (0.2% O2) was 
also given to the cells with standard FBS-containing medium, before exploring the 
protection of hypoxic preconditioning against AcS. 
Metabolic activity, cell counts and proliferation assays 
A 20% MTS Tetrazolium and PMS solution was added to the cells and incubated for 
4 hours at 37°C. Absorbance (OD) was measured at 490 nm and 650nm as a reference 
wavelength. Subsequently, nuclei were stained with Hoechst 33342 in the dark for 20 
mins at room temperature and washed with PBS. Cell counts were operated with a high 
content screener using the Hoechst 33342 channel (excitation/emission: 380/445 nm). 
The cell survival rate is depicted as the percentage of cells counted after I/R, compared 
to cells plated. BrdU incorporation was used to quantify cell proliferation. Cells cultured 
in 96-well plates were first incubated with BrdU labeling solution at 37°C for 4 hours and 
finished the remaining steps according to the manual.  No stop solution was used at the 
end of the assay, so absorbance was measured in the ELISA reader at 370 nm with the 
reference wavelength set at 492 nm. 
Apoptosis detections assays 
In these experiments, two different assays to quantify apoptosis were performed. 
Fluorochrome-labeled inhibitors of caspase assays were used to detect caspase activity 
in CB-MSCs. The poly-caspase probe (SR-VAD-FMK) recognizes all different types of 
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activated poly-caspases. The cells were incubated with the poly-caspase probe for 45 
minutes at 37°C, with gentle agitation every 10 minutes. Then, nuclear counterstain with 
Hoechst 33342 was performed. Cells were then scanned with the high content screener 
using the Alexa 568 (excitation/emission: 570/615 nm) and Hoechst 33342 
channels.  Data were analyzed using the Columbus software.   
Additionally, a differentiated detection for the late and early stages of apoptosis was 
performed by Annexin V and Ethidium Homodimer III staining. CB-MSCs were harvested 
after I/R and stained according to the provided protocol. Cells under normal cultivation 
were used as the negative control, cells treated with 24 hours of 200uM H2O2 as Annexin 
V positive control, and cells incubated on ice after 10 minutes of 65°C warm water bath 
as Ethidium homodimer III positive control. Fluorescence was measured using a 
MacsQuant VYB and analyzed by FlowJo 10. 
Real-time RT-PCR 
Cells were harvested after the programmed procedures and stored at -20°C.  Total 
RNA was isolated using the NucleoSpin RNA isolation kit. The purity and integrity of 
isolated RNA were assessed by spectrophotometry and gel electrophoresis. RNA 
samples from biological replicates were pooled, before cDNA synthesis to account for 
biological variation223. cDNA was synthesized by reverse transcription using the qScript 
SuperMix. Expression of 96 gene associated apoptosis and cell cycle pathways were 
tested using qPCR array kits from Realtimeprimers.com, using their recommended 
amplification protocol. 
∆CT=CT(genes of interest)-CT(housekeeping genes HPRT1) 
For apoptosis-related gene regulations: 
∆∆CT=∆CTafter AcS-∆CTbefore AcS 
For cell-related gene regulations: 
∆∆CTcompared to before AcS=∆CT3d after AcS-∆CTbefore AcS 
∆∆CTcompared to FBS=∆CThuman sera-∆CTFBS 
Fold gene expression=2-∆∆CT 
Statistics 
Data were obtained from results comparing groups of at least 3 separate biological 
samples. With a normal distribution, data are shown as mean ± SD. Levene test was 
performed to test the homogeneity of variances. One-way ANOVA was then executed to 
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analyze differences between groups. If the assumption of equal population variance was 
accepted, Tukey’s post hoc analysis was carried out between equal amounts of samples, 
and Games-Howell tests among inequal numbers of samples. If the null assumption was 
rejected, Welch ANOVA and Games-Howell post hoc tests were performed. In the case 
of skewed distribution, data are shown as medium [25%, 75% percentile]. Kruskal-Wallis 
tests were then performed. Differences were considered statistically significant at P<0.05. 
Statistical analyses were performed using the IBM SPSS Statistics software Version 22. 
 
Table 6. Project experimental materials 
  Company  Country 
Instruments & Tools     
Microscopy  
Carl Zeiss MicroImaging 
GmbH 
 Göttingen, Germany 
Balance, new classic MF  Mettler Toledo  Columbus, Ohio, USA 
Eppendorf pipettes  Eppendorf AG  Hamburg, Germany 
Centrifuge  Beckman Coulter GmbH  Krefeld, Germany 
Cell culture flow hood; SAFE 2020  
Thermo Fisher Scientific 
Corporation 
 Waltham, Massachusetts, USA 
Freezing container; Mr. Frosty  
Thermo Fisher Scientific 
Corporation 
 Waltham, Massachusetts, USA 
Incubator  Binder GmbH  Tuttlingen, Germany 
Hypoxic incubator  Binder GmbH  Tuttlingen, Germany 
Microplate reader: SpectraMax  Molecular Devices, LLC  San Jose, California, USA 
High content screen: Operetta®  PerkinElmer, Inc  Waltham, Massachusetts, USA 
Spectrophotometer: Nanodrop™ 
2000/2000c 
 Thermo Fisher Scientific  Wilmington, Delaware USA 
Real time PCR machine: QuantStudio 
6 Flex 
 Applied Biosystems  Foster City, California, USA 
Flow cytometry: MACSQuant® VYB  Miltenyi Biotec GmbH  Bergisch Gladbach, Germany 
Vacutainer Safety-Lok blood 
collection set 
 BD Medical  Hamburg, Germany 
Reagents & Kits     
DMEM Glutamax+, Gibco, 1g/L 




 Carlsbad, California, USA 




 Carlsbad, California, USA 
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Table 6. Project experimental materials 
  Company  Country 
DPBS, invitrogen: -/-; +/+  
Thermo Fisher Scientific 
Corporation 
 Carlsbad, California, USA 
Trypan blue solution 0.4%  Sigma-Aldrich  St. Louis, Missouri, USA 





 Carlsbad, California, USA 
Penicillin/streptomycin, Gibco  
Life Technologies 
Corporation 
 Carlsbad, California, USA 
FBS/FCS, Gibco  
Life Technologies 
Corporation 
 Carlsbad, California, USA 
Paraformaldehyde  Carl Roth GmbH&Co.Kg  Karlsruhe, Germany 
Ethanol 100%  Carl Roth GmbH&Co.Kg  Karlsruhe, Germany 





 Carlsbad, California, USA 
Agarose molecular grade  Bioline GmbH  Luckenwalde, Germany 
Ethidium bromide  Carl Roth GmbH&Co.Kg  Karlsruhe, Germany 
RNase Zap  Ambion, Inc  Foster City, California, USA 
NAN3  Carl Roth GmbH&Co.Kg  Karlsruhe, Germany 
Hoechst 33342, molecular probes™  Thermo Fisher Scientific  Wilmington, Delaware USA 
CellTiter 96 Aqueous Non-
Radioactive Cell Proliferation Assay 
 Promega GmbH  Madison, Wisconsin, USA 
Cell proliferation ELISA BrdU, 
colorimetric 
 Roche Holding AG  Basel, Switzerland 
Apoptosis/necrosis detection kits  PromoCell GmbH  Heidelberg, Germany 
Mycoalert kits  Lonza Group  Basel, Switzerland 
RNA isolation kits, Nucleospin  
MACHEREY-NAGEL GmbH 
& Co. KG 
 Düren, Germany 
Qscript cDNA Supermix  
Quantabio Reagent 
Technologies 
 Beverly, Massachusetts, USA 
Power sybr green master mix  Applied Biosystems  Foster City, California, USA 
Pierce BCA protein assay kit  
Thermo Fisher Scientific 
Corporation 
 Waltham, MA, USA 
Hyperladder 1kb  Bioline GmbH  Luckenwalde, Germany 
Apoptosis & cell cycle primer sets  RealTimePrimers.com  Elkins Park, Philadelphia, USA 
Consumables     
Cell culture flasks  Greiner Bio-One GmbH  Kremsmünster, Austria 
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Table 6. Project experimental materials 
  Company  Country 
96-well culture plate, transparent, 
CELLSTAR 
 Greiner Bio-One GmbH  Kremsmünster, Austria 
Falcon tubes  Corning Inc.  Corning, New York, USA 
Eppendorf tubes  Eppendorf AG  Hamburg, Germany 
Software     
Columbus software  PerkinElmer, Inc  Waltham, Massachusetts, USA 
FlowJo 10  FlowJo LLC  Ashland, OR, USA 
Spss statistics® 22  IBM Corporation  Somers, New York, USA 




Characteristics of serum donors 
From June to December 2014, sera were collected from 12 patients and 12 healthy 
volunteers. As presented in Table 7, healthy volunteers were significantly younger, but 
with a narrower age distribution (54±5.8, 46-61 years old) compared to patient donors 
(64±11.8, 44-89 years old). 5 out of 12 healthy donors were female, but among patient 
donors, the ratio of female to male was 1:3. Only eight patients had a history of myocardial 
infarction, and all 12 were diagnosed with ischemic heart diseases during hospitalization, 
2 of whom had two-vessel coronary artery diseases, and the other 10 had three-vessel 
diseases. In terms of NYHA functional status, five patients were classified to be at level 
III, and the remaining seven at level IV; additionally, reduced left ventricular ejection 
fraction was distributed from 15% to 36% on an average of 22 ± 7.1% among the patients. 
Other characteristics concerning left ventricular end-diastolic diameter (LVEDD) and drug 
usage are described in Table 7. Additionally, no significance for total protein 
concentrations was found between the two groups. The lowest protein concentration was 
46.6 g/L in an HF2 patient. Therefore, the subsequent medium sera were neutralized by 
this lowest concentration. 
 
Table 7. Demographics and patient characteristics 




History   
Age 54±5.8* 64±11.8 
Gender [male/female] 7/5 9/3 
Smoker 2 2 
Ex-smoker 3 10 
Previous MI - 8 
Time since most recent MI (years) - 8±9.6 (0-25) 
Extend of CAD   
Two vessels - 2 
Three vessels - 10 
NYHA functional class   
III - 5 
IV - 7 
Left ventricular end diastolic diameter (LVEDD)[mm] - 65±9.5 
Left ventricular ejection fraction (LVEF)[%] - 22±7.1 
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Table 7. Demographics and patient characteristics 




Non-cardiac disease   
Reynaud syndrome 1 - 
Pulmonary hypertension - 3 
Drug usage   
Anticoagulant - 9 
Anti-platelet agent - 4 
Anti-arrhythmic agent - 7 
Cardiac glycoside - 5 
Sympathomimetic drug - 5 
Adrenergic receptors blocker - 8 
ACE inhibitors - 10 
Xanthine oxidase inhibitor - 1 
Acetylsalicylic acid - 4 
Proton-pump inhibitor - 4 
Diuretics - 11 
Hypolipidemics - 4 
Pain reliever - 6 
Insulin - 3 
Vasodilator - 7 
Calcium channel blocker - 1 
H2 receptor antagonist - 3 
Aromatic L-amino acid decarboxylase - 1 
Bronchial spasms reliever - 1 
Nausea and vomiting - 4 
Antibiotics - 5 
PAH treat - 1 
Synthetic thyroid hormone 1 1 
Lower uric acid levels - 1 
Schizophrenia - 1 
Protein concentration 59.07±5.42 55.28±4.68 
*p=0.013 between the ages of HFS and CS donors 
 
CB-MSCs become more proliferative under human serum cultivation 
As shown by previous publications, the overall morphology or immunophenotype of 
the cells was unaffected by the cultivation of CB-MSCs with human sera from either 
healthy individuals or HF patients221. As expected, human sera resulted in a higher 
variation in cell accrual than FBS, a standardized, pooled tissue culture supplement 
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(Figure 9A). The BrdU incorporation assay confirmed more active cell division in cells 
cultured under human sera (Figure 9B). Since day 3, the OD value, reflecting BrdU 
incorporation activity in cells with FBS, remained at only 0.033 [0.016, 0.077], an 
impressive drop compared to the human sera group. BrdU incorporation at day 5 also 
dropped in human sera groups compared to day 3. But this phenomenon could be 
partially explained by their high percentage of confluence on day 5 (cell numbers: 19414 
[18703, 20660] in the CS group and 16261 [14924, 22266] in HFS group). In addition, 
cells from three groups all presented as thin, spindle-shaped, and fibroblast-like (Figure 
9D- F). Cells with HF sera were at higher levels of metabolic activity than those with 
 
Figure 9. Proliferation and metabolism profiles of CB-MSCs under standard cultivation 
Cell accrual (A), DNA synthesis (B), and metabolic activity (C) of CB-MSCs were evaluated with different medium 
serum under normal conditions (glucose /L, 21% O2). After 5 days of expansion in two different conditions, cells 
with three types of medium sera were captured under microscopy (20X) (D, E, F). 
In Figure A, data are shown as medium [25%, 75% percentile]. In Figures B and C, box plots are shown with 
Tukey Whiskers, and black dots are seen as outliers. 
ap stands for p value between CS and FBS groups. bp stands for p value between HFS and FBS groups.  
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control sera during 5 days. At day 3, CB-MSCs under HFS demonstrated themselves with 
a significantly more active cellular metabolic rate (0.13 ± 0.03 compared to 0.1 ± 0.02 with 
CS, p=0.034). These effects were undetectable at day 5 (p=0.201) (Figure 9C).  
Human serum protects CB-MSCs against acute oxidative stress 
Next, we designed a model of acute stress (AcS) imitating an oxidative stressful 
condition during the process of cell engraftments, which is based on previously published 
models of ischemia/reperfusion injury224,225. In preliminary experiments, we established 
the combination of 4 hours of hypoxia at 0.2% O2, and glucose and serum deprivation 
followed by standard culture conditions that were sufficient for reproducibly induced 
significant cell loss during AcS. Immediately after acute stress, the salvage of cells 
cultured with HFS (60.02% ± 13.65%) and CS (65.79% ± 16.03%) was significantly higher 
than cells treated with FBS (45.08% ± 7.42%) (p=0.035 vs. p=0.006, respectively) (Figure 
10 A), but there were only mild non-significant differences in cell survival between HFS 
and CS (p=0.376). Interestingly when we performed Annexin V and EthD-III stainings 
after AcS, we uncovered that in the HFS group, the presence of apoptotic cells (Annexin 
V+) was significantly lower than FBS group (9.02% [8.62%, 11.59%] vs. 13.15% [12.09%, 
16.60%], p=0.025), and that of live cells (Annexin V-/ EthD-III-) was higher (Figure 10B). 
Comparatively, control sera were shown to protect stem cells against acute stress, 
additionally brought a faster recovery in cell proliferation (Figure 10C - 1day after AcS). 
Hypoxic preconditioning increases resistance against AcS of CB-MSCs with FBS 
High cell survival is one of the critical factors for successful cell transplantation and 
the consequent stem cell-induced cardiac repair. In the previous paragraph, we 
demonstrated the superiority of human serum-cultured cells against oxidative stress 
during cell transplantation. On the other hand, the disadvantage of human serum 
application is also clear: limited supply, especially from HF donors. To replace human 
sera, but maintain the anti-oxidative property, we repeated AcS in all groups of CB-MSCs 
preconditioned with hypoxia. Consistent with our preliminary data, FBS cultured cells had 
an increased cell survival after AcS with 81.44% [43.25%, 93.94%] cells left (Figure 10D). 
Through flow cytometry, no significance was found in either dead cells, apoptotic cells, or 




Figure 10. Cell survival profiles of CB-MSCs after AcS 
After 4 hours of simulated acute stress without any preconditioning, the numbers of survival CB-MSCs were counted (A), and apoptotic, dead, or live cells were stained and 
assessed through flow cytometry (B). Subsequently, the recoveries of cell proliferation were continuously tracked until 5 days after AcS (C). Hypoxic preconditioning was also 
applied to test the benefits of this pretreatment on CB-MSCs against AcS (D-F). 
In Figures AB and DE, box plots are shown with Tukey Whiskers, and black dots are seen as outliers. In Figure C, F, data were shown as medium [25%, 75% percentile] 
ap stands for p value between CS and FBS groups.  
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Potential genes involved in cell 
survival and recovery after AcS 
As described previously, human 
sera in CB-MSCs cultivation 
presented an anti-oxidative stress 
property; meanwhile, the gap of cell 
survival between FBS and human 
sera was successfully covered by 
hypoxic preconditioning. To figure out 
how genes modulated during this 
process, genes of interest from cells 
treated with different sera and 
conditions were measured for 
intracellular expressions immediately 
after AcS compared to before. Nine 
genes were chosen for gene 
expression analysis based on the key 
roles of their expressed products 
during apoptosis. Oxidative stress 
leading to DNA damage, 
mitochondrial dysfunction, and 
activation of the Fas/FADD pathway finally induce cellular apoptosis. 
According to Figure 11, during activated apoptosis, gene expressions of caspase 8, 
DFFA, tp53, ATM, and Bcl-2 were downregulated in cells cultured with FBS. A similar 
pattern of gene modulations was shown in cells under control serum additionally with 
reduced BAX, ATR, and APAF1 expressions. ATR was additionally suppressed in cells 
treated with control sera, and the downstream transcription Tp53 was also suppressed, 
which blocks Bcl-2 and activates BAX so as to modulate the stability of the mitochondrial 
membrane. APAF1, the critical proteins that combine with cytochrome C, leaked from 
swallowed and dysfunctional mitochondria and then triggering caspase cascade, were 
also downregulated, while the expression profiles were different in cells with HF sera. 
Only ATM and Bcl-2 were downregulated by over 2-fold compared to before AcS. 
 
Figure 11. Apoptosis-related gene expression profiles of 
CB-MSCs under different situations. 
Samples were taken after programmed ischemia-
reperfusion injury, and their gene expressions were 
compared to before I/R. 
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Compared to FBS cultivation, additional hypoxia preconditioning showed unchanged 
Tp53 and ATR expressions. 
Three days after giving AcS, cells cultured with human sera had doubled cell counts 
compared to FBS as previously shown. Gene expression levels (Figure 12A-B) reveal a 
more active cell cycle-related gene expression in cells with HF sera, and both were 
compared to FBS and to before AcS. Expression of cyclin encoding genes as CCNA2, 
CCNB1, CCND1, and CCNE1 in addition to cycle-dependent kinases, CDC2 and CDK2, 
were up-regulated. Those gene expressions did not increase in cells with control sera 
compared to FBS and even decreased compared to before AcS. In contrast, we saw an 
increase in RB, CDKN1A, and CDKN1B-2 expressions in comparison to FBS, which all 
negatively modulate cell cycles (Figure 12A). Limited alterations in gene expression in 
FBS are shown in Figure 12B except for a highly elevated RB level.  
 
Figure 12. Cell cycle-related gene expression profiles of CB-MSCs under different situations 
Samples were taken 3 days after programmed cell injury. 
(A) Related gene expressions of cells with human sera compared to FBS 




Impact of aging on cells and the microenvironment 
Since regenerative capacity was discovered to be impaired in aged stem cells, 
concern about the age threshold in the clinical application of stem cells has been raised226. 
As we know, to reach sufficient cell doses for transplantation, harvested primary cells are 
confronted with replicative stress. After repeated cell division in a short period of time, 
telomere length would be rapidly shortened227. Consequently, damaged DNAs 
accumulate and eventually undermine intrinsic maintenance228. Those aging stem cells 
with shorter telomere length exhibit weaker proliferative capacity and impaired 
regenerative functions229. It also means that stem cells from old donors have impaired 
proliferation, and affects potential for cardiac repair, while this is likely to be less of an 
issue in cells from young donors63,230.  
When cells are successfully engrafted into an old and dysfunctional heart, the aging 
microenvironment also influences stem cell properties. As the long history of parabiosis 
and anti-aging research has shown us, aging serum could harm the rejuvenation capacity 
of progenitor cells, e.g. by prolonging population doubling time, and by increasing the 
number of senescent cells231,232. However, other research discovered that young 
progenitor cells were more resistant to this negative effect. Young stem cells still 
maintained more proliferative and juvenile surface markers, while in old cells, they were 
rapidly lost after overnight culturing with old sera233. 
Applications of different sera 
As the most applied media serum in the current clinical application, FBS has been 
shown to downregulate a wide range of gene expressions in regard to several aspects 
including cell proliferation, cell differentiation, paracrine secretion and metabolism175. In 
our results, cells cultured with FBS showed less proliferative capacity in standard 
cultivation compared to cells with human sera. Alternations in gene expression level is 
discussed in detail in the next section. Therefore, to reach minimum dose for cell infusion 
in clinical use, human sera is a better choice since they could spare a lot of incubation 
time. 
Choosing either autologous patient sera or allogeneic healthy sera is another issue. 
In our experiment, we saw that the cell counts in the HF serum group all fell behind the 
control serum groups, but there was no statistical significance regarding this observed 
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difference. At the molecular level, higher activities in mitochondrial metabolism were 
found in the HF serum group under standard cultivation, with insignificantly faster DNA 
duplication. Moreover, several cell cycle-related genes were also seen upregulated 
during cell recovery. However, we failed to match the ages of human sera during sera 
donations where HF sera donors were 9 years older than controls. Thus, we could not 
eliminate the possibility entirely that donor age affected our proliferation profiles. On the 
other hand, it is more likely that the different performance between control and HF serum 
groups and their inconsistencies are due to drug usage, not age. In total, up to 25 different 
types of drugs were used on HF serum donors during hospitalization. For instance, 
heparin was used in 6 out of 12 patient donors at the time of blood withdrawal, and heparin 
was reported to promote the growth of human stem cells through activating FGF signaling, 
but could also be deleterious at a higher concentration234. Another conventional 
medication that was used in HF patients is aspirin, which prevents platelet accumulation, 
and is proven to inhibit MSC cell growth during in vitro cultivation235. Simvastatin, HMG-
CoA reductase inhibitor, was even found to induce apoptosis by activating Bax and 
downregulating Bcl-2. Conversely, only synthetic thyroid hormone was used in healthy 
volunteers. 
Metabolism of stem cells and the model setup of acute stress (AcS) 
Under physiological conditions, aerobic metabolism is the most efficient way of 
utilizing nutrients and providing energy in normal human cells in which the glycolytic 
metabolism, which is an oxygen-independent metabolic pathway, is suppressed. 
However, it is highly activated under hypoxia or anoxia. Stem cells are thought to be more 
resistant to oxidative stress as they have been found to have a higher level of glycolytic 
metabolism; the switch from oxidative phosphorylation to glycolysis has been observed 
during iPSC reprogramming236,237. Therefore, compared to other cell types, stem cells 
could more quickly respond and adjust to a change of microenvironment. 
However, after cell retention in the injured myocardium, stem cells are exposed to a 
microenvironment not only characterized by low tissue oxygenation but also by 
insufficient nutrition supply and an accumulation of metabolic wastes. We set up a 
simulated condition with 0.2% O2 and glucose starvation to mimic a similar condition in 
infarcted myocardium. 0.2% O2 is the minimum hypoxic condition that we could give for 
in vitro treatments but is not sufficient to create enough oxidative stress on CB-MSCs due 
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to active glycolysis. Therefore, we also used basal media without glucose to enhance pro-
apoptotic stress. 
Alterations in gene expressions after programmed AcS  
The stem cells in control serum showed a superior anti-oxidative capacity. As 
depicted and described in Figure 13A, several critical pro-apoptotic proteins, such as 
ATR, Tp53, Bax, Apaf1, caspase 8, and DFFA were downregulated after AcS. The 
suppression of their expression explained the upraised cell survival in the cells treated 
with human sera. We expected an up-regulated expression of Bcl-2; however, 
downregulation actually appears to have occurred. Its intracellular level was reported to 
be inversely correlated with ROS240,241, which could explain the negatively modulated 
expression of BCL-2 under programmed AcS. Different from control serum, HF serum did 
not suppress the expressions of most pro-apoptotic genes of interest except ATM and 
Apaf1. Of note, the expression of Apaf1 was elevated, indicating an increase in activation 
of the downstream caspase cascade. Considering that the survival rate of cells after AcS 
with HF serum is similar to those with control serum, another anti-apoptotic mechanism 
and pattern gene modulations are implied in cells in HF sera. 
Hypoxic preconditioning is a popular method of drug-free pretreatment against 
ischemia-reperfusion injury242. The preconditioning could decrease the formation of 
intracellular reactive oxygen species and consequently decrease cell death during 
ischemic injury243. Pretreated stem cells have enhanced survivability, and pro-angiogenic 
capacity, which was confirmed both in vitro and in vivo; hence, they have been widely 
used in the regeneration of multiple organs225,244,245. The enhanced survivability of stem 
cells after hypoxic pretreatment was proven in our experiment after raising stem cell 
survival rates from 45.08% to 81.44%. Interestingly, the expressions of ATR and Tp53 
were slightly suppressed after AcS in the group without hypoxic pretreatment while they 
were unchanged in the hypoxia pretreated group. These two encoded proteins play 
essential roles in the cell response to DNA damage and cell adaptation to apoptotic stress 
(Figure 13A). Under severe hypoxia (0.2% O2 or even less), ATR was reported to be 
activated through the regulation of hypoxia-inducible factor 1(HIF-1), and positively 
regulate this factor’s expression in the feedback. This finding implies that the maintenance 
of ATR expression might be helpful for cellular adaptation to severe hypoxia246. Besides 
that, the translation of Tp53 was also reported to be enhanced by HIF-1α247,248. Thus, the 







Figure 13. Modulations of apoptosis-related genes in response to AcS and cell cycle-related genes in recovery. 
The two pathways were drawn based on the information provided by the KEGG pathway database. 
(A) This plot used ko04210 and ko04115 from the KEGG pathway database for references. ATM is the protein 
kinase that is recruited when DNA double-strand breaks in response to stimuli and mediates the activation of 
Tp53. Activated Tp53 leads to the inhibition of Bcl-2 and induction of Bax and promotes apoptosis238. Bax and Bcl-
2 are both localized to the mitochondrial membrane. Bax opens the mitochondrial voltage-dependent anion 
channel (VDAC), subsequently leading to the release of cytochrome C, which then binds to APAF. Another 
pathway to apoptosis is mediated through caspase-8. The stimuli come from the membrane by reactive oxygen 
species (ROC), generated during ischemia. Pro-caspase 8 is then cleaved and then generates mature caspase 8. 
Both pathways trigger caspase cascade and lead to the cleavage of DFFA. Subsequently, DFFB activated by 
DFFA cleavage triggers DNA fragmentation and chromatin condensation239. 
(B) This plot used ko04110 from the KEGG pathway database for references. To duplicate, stem cells must go 
through 4 different cell cycle phases: G1, S, G2 and M. Cyclins, such as Cyclin D, E, A, B, combined with their 
dependent kinases (CDKs), such as cdk2,4,6 and cdc2, regulate the transition from one cell cycle phase into the 
next. Cyclin-dependent kinase inhibitors (CDKNs), such as CDKN1A, 1B-2, 1B-3, 2B, 2C, and 2D, arrest the cell 
cycle through binding and inactivating cyclin-CDK complexes. Retinoblastoma protein (RB) is another protein that 
keeps cells in the G1 phase by restricting DNA synthesis. 
The URL address of ko04210 is: 
https://www.kegg.jp/kegg-bin/show_pathway?ko04210+K04451 
The URL address of ko04115 is: 
https://www.kegg.jp/kegg-bin/show_pathway?ko04115+K04451 




probably maintain cell pro-survival capabilities after severe oxidative stress. 
Research related to stem cell recovery after severe ischemia, both in vitro and in vivo, 
is still rare. We observed an impaired proliferative potential of cord blood-derived 
mesenchymal stromal cells after AcS. Cell counts in human serum groups were up to 
20,000 per well under standard conditions but only reached between 10,000 and 15,000 
at the end of recovery. Three days after programmed AcS, cell expansion seemed to 
have ceased or become much slower. RT-PCR results from cells with control sera 
revealed similar cell cycle-related gene modulations as those in FBS. Expressions of 
CCNA2, CCNB1, and CDC2 were suppressed after AcS compared to the normal 
condition. These gene expression profiles showed a consistent performance with its 
halted expansion in cell culture plates at three days after AcS. In this study, we assumed 
that AcS might impair the proliferative potential of CB-MSCs. However, the expansion of 
cells with HF sera also ceased, but cell duplication appeared quite active in gene 
expression levels. Other than RB, the cell-cycle-related gene modulations in FBS were 
quite limited. RB is a critical tumor suppressor protein that puts the cell cycle into the G0 
phase. The high expression of RB with FBS implies a different mechanism of cell cycle 
suppression from cells with human serum. 
Conclusion 
In this study, we were able to confirm that CB-MSCs expanded in human sera had 
better proliferative profiles than those expanded in FBS; higher survival rate after AcS 
indicated that they were more resistant to severe oxidative stress. However, differences 
between both heart failure and control sera were not found related to their proliferation 
capacity or survivability under ischemia-reperfusion injury. Relevant gene modulations in 
response to AcS were significantly different among sera. Hypoxic preconditioning 
improved the survivability of CBMSCs under FBS cultivation. Suppression of cell cycle 
The element picture of DNA breakdown was modified. Its original URL address is: 
http://www.merckmillipore.com/INTERSHOP/static/WFS/Merck-Site/-/Merck/en_US/Freestyle/BI-
Bioscience/Antibodies-Assays/cancer-images/double-helix-break.gif 
The element picture of mitochondrial was also modified. Its original URL address is: 
http://www.alsresearchforum.org/wp-content/uploads/03.03_Nature-Li-Mitochondria_clear_proteins_NV-1.jpg 
Both were downloaded and then modified in December 2018. 




progression after AcS was detected in cells in all three different medium sera, but it 
worked in different ways.  
Expansion of stem cells by using either human sera or programmed hypoxic 
pretreatment is a good alternative to FBS in normal conditions. In the preventative therapy 
of stem cells infusion for post-operative complications after long cardiac surgeries, 
especially for preventing myocardial injury related to CPB or surgery trauma, stem cells 
with human sera or hypoxic pretreatment could have a better resistance against oxidative 
stress, which is the ischemia-reperfusion injury that occurs in heart tissues when 
removing from CPB. By using the above-mentioned strategies, we optimized CB-MSCs 
to increase their survivability in the oxidative stressful condition after transplantation into 
hearts, therefore, to increase their retention rate in order to provide better cardioprotection 
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